Alpha Synuclein: Neurodegeneration and Inflammation
Abstract
:1. Introduction
2. Alpha-Synuclein Oligomers
2.1. Oligomers and Transmission of LB Pathology
2.2. Oligomer Neurotoxicity
3. Alpha-Synuclein and Inflammation
3.1. Peripheral and Central Inflammation
3.2. Inflammation and α-Syn oligomers
3.3. Role of Astrocytes
4. Therapeutic Perspectives
4.1. Synuclein Aggregation as a Pharmacological Target
4.2. Immunotherapy
4.3. Anti-Inflammatory Treatments
5. Conclusions
Funding
Conflicts of Interest
References
- Braak, H.; Del Tredici, K.; Rüb, U.; de Vos, R.A.; Jansen Steur, E.N.; Braak, E. Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol. Aging 2003, 24, 197–211. [Google Scholar] [CrossRef]
- De Nuccio, F.; Kashyrina, M.; Serinelli, F.; Laferrière, F.; Lofrumento, D.D.; De Giorgi, F.; Ichas, F. Oligodendrocytes Prune Axons Containing α-Synuclein Aggregates In Vivo: Lewy Neurites as Precursors of Glial Cytoplasmic Inclusions in Multiple System Atrophy? Biomolecules 2023, 13, 269. [Google Scholar] [CrossRef] [PubMed]
- Lennox, G.; Lowe, J.; Morrell, K.; Landon, M.; Mayer, R.J. Anti-ubiquitin immunocytochemistry is more sensitive than conventional techniques in the detection of diffuse Lewy body disease. J. Neurol. Neurosurg. Psychiatry 1989, 52, 67–71. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Krüger, R.; Kuhn, W.; Müller, T.; Woitalla, D.; Graeber, M.; Kösel, S.; Przuntek, H.; Epplen, J.T.; Schöls, L.; Riess, O. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson’s disease. Nat. Genet. 1998, 18, 106–108. [Google Scholar] [CrossRef] [PubMed]
- Polymeropoulos, M.H.; Lavedan, C.; Leroy, E.; Ide, S.E.; Dehejia, A.; Dutra, A.; Pike, B.; Root, H.; Rubenstein, J.; Boyer, R.; et al. Mutation in the alpha-synuclein gene identified in families with Parkinson’s disease. Science 1997, 276, 2045–2047. [Google Scholar] [CrossRef] [Green Version]
- Ueda, K.; Fukushima, H.; Masliah, E.; Xia, Y.; Iwai, A.; Yoshimoto, M.; Otero, D.A.; Kondo, J.; Ihara, Y.; Saitoh, T. Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease. Proc. Natl. Acad. Sci. USA 1993, 90, 11282–11286. [Google Scholar] [CrossRef] [Green Version]
- Yoshimoto, M.; Iwai, A.; Kang, D.; Otero, D.A.; Xia, Y.; Saitoh, T. NACP, the precursor protein of the non-amyloid beta/A4 protein (A beta) component of Alzheimer disease amyloid, binds A beta and stimulates A beta aggregation. Proc. Natl. Acad. Sci. USA 1995, 92, 9141–9145. [Google Scholar] [CrossRef] [Green Version]
- Spillantini, M.G.; Schmidt, M.L.; Lee, V.M.Y.; Trojanowski, J.Q.; Jakes, R.; Goedert, M. α-Synuclein in Lewy bodies. Nature 1997, 388, 839–840. [Google Scholar] [CrossRef]
- Spillantini, M.G.; Crowther, R.A.; Jakes, R.; Hasegawa, M.; Goedert, M. α-Synuclein in filamentous inclusions of Lewy bodies from Parkinson’s disease and dementia with lewy bodies. Proc. Natl. Acad. Sci. USA 1998, 95, 6469–6473. [Google Scholar] [CrossRef] [Green Version]
- Colom-Cadena, M.; Pegueroles, J.; Herrmann, A.G.; Henstridge, C.M.; Muñoz, L.; Querol-Vilaseca, M.; Martín-Paniello, C.S.; Luque-Cabecerans, J.; Clarimon, J.; Belbin, O.; et al. Synaptic phosphorylated α-synuclein in dementia with Lewy bodies. Brain 2017, 140, 3204–3214. [Google Scholar] [CrossRef] [PubMed]
- Fujiwara, H.; Hasegawa, M.; Dohmae, N.; Kawashima, A.; Masliah, E.; Goldberg, M.S.; Shen, J.; Takio, K.; Iwatsubo, T. alpha-Synuclein is phosphorylated in synucleinopathy lesions. Nat. Cell Biol. 2002, 4, 160–164. [Google Scholar] [CrossRef] [PubMed]
- Albani, D.; Peverelli, E.; Rametta, R.; Batelli, S.; Veschini, L.; Negro, A.; Forloni, G. Protective effect of TAT-delivered alpha-synuclein: Relevance of the C-terminal domain and involvement of HSP70. FASEB J. 2004, 18, 1713–1715. [Google Scholar] [CrossRef] [PubMed]
- Bartels, T.; Choi, J.G.; Selkoe, D.J. α-Synuclein Occurs Physiologically as a Helically Folded Tetramer that Resists Aggregation. Nature 2011, 477, 107–110. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Wang, W.; Perovic, I.; Chittuluru, J.; Kaganovich, A.; Nguyen, L.T.T.; Liao, J.; Auclair, J.R.; Johnson, D.; Landeru, A.; Simorellis, A.K.; et al. A Soluble α-Synuclein Construct Forms a Dynamic Tetramer. Proc. Natl. Acad. Sci. USA 2011, 108, 17797–17802. [Google Scholar] [CrossRef] [Green Version]
- Xu, L.; Bhattacharya, S.; Thompson, D. On the ubiquity of helical α-synuclein tetramers. Phys. Chem. Chem. Phys. 2019, 21, 12036–12043. [Google Scholar] [CrossRef]
- Dettmer, U.; Newman, A.J.; von Saucken, V.E.; Bartels, T.; Selkoe, D. KTKEGV repeat motifs are key mediators of normal α-synuclein tetramerization: Their mutation causes excess monomers and neurotoxicity. Proc. Natl. Acad. Sci. USA 2015, 112, 9596–9601. [Google Scholar] [CrossRef] [Green Version]
- Forloni, G.; La Vitola, P.; Balducci, C. Oligomeropathies, inflammation and prion protein binding. Front. Neurosci. 2022, 16, 822420. [Google Scholar] [CrossRef]
- Burré, J.; Vivona, S.; Diao, J.; Sharma, M.; Brunger, A.T.; Südhof, T.C. Properties of Native Brain α-Synuclein. Nature 2013, 498, E4–E6, discussion E6–E7. [Google Scholar] [CrossRef] [Green Version]
- Dettmer, U.; Newman, A.J.; Soldner, F.; Luth, E.S.; Kim, N.C.; von Saucken, V.E.; Sanderson, J.B.; Jaenisch, R.; Bartels, T.; Selkoe, D. Parkinson-Causing α-Synuclein Missense Mutations Shift Native Tetramers to Monomers as a Mechanism for Disease Initiation. Nat. Commun. 2015, 6, 7314. [Google Scholar] [CrossRef] [Green Version]
- Fonseca-Ornelas, L.; Stricker, J.M.S.; Soriano-Cruz, S.; Weykopf, B.; Dettmer, U.; Muratore, C.R.; Scherzer, C.R.; Selkoe, D.J. Parkinson-causing mutations in LRRK2 impair the physiological tetramerization of endogenous α-synuclein in human neurons. NP J. Parkinsons. Dis. 2022, 8, 118. [Google Scholar] [CrossRef]
- Gao, V.; Briano, J.A.; Komer, L.E.; Burré, J. Functional and Pathological Effects of α-Synuclein on Synaptic SNARE Complexes. J. Mol. Biol. 2023, 435, 167714. [Google Scholar] [CrossRef] [PubMed]
- Sharma, M.; Burré, J. α-Synuclein in synaptic function and dysfunction. Trends Neurosci. 2023, 46, 153–166. [Google Scholar] [CrossRef] [PubMed]
- Frieg, B.; Antonschmidt, L.; Dienemann, C.; Geraets, J.A.; Najbauer, E.E.; Matthes, D.; de Groot, B.L.; Andreas, L.B.; Becker, S.; Griesinger, C.; et al. The 3D structure of lipidic fibrils of α-synuclein. Nat. Commun. 2022, 13, 6810. [Google Scholar] [CrossRef] [PubMed]
- Fusco, G.; De Simone, A.; Gopinath, T.; Vostrikov, V.; Vendruscolo, M.; Dobson, C.M.; Veglia, G. Direct Observation of the Three Regions in α-Synuclein That Determine Its Membrane-Bound Behaviour. Nat. Commun. 2014, 5, 3827. [Google Scholar] [CrossRef] [Green Version]
- Fusco, G.; Chen, S.W.; Williamson, P.T.F.; Cascella, R.; Perni, M.; Jarvis, J.A.; Cecchi, C.; Vendruscolo, M.; Chiti, F.; Cremades, N.; et al. Structural basis of membrane disruption and cellular toxicity by α-synuclein oligomers. Science 2017, 358, 1440–1443. [Google Scholar] [CrossRef] [Green Version]
- Borghi, R.; Marchese, R.; Negro, A.; Marinelli, L.; Forloni, G.; Zaccheo, D.; Abbruzzese, G.; Tabaton, M. Full length alpha-synuclein is present in cerebrospinal fluid from Parkinson’s disease and normal subjects. Neurosci. Lett. 2000, 287, 65–67. [Google Scholar] [CrossRef]
- Kordower, J.H.; Chu, Y.; Hauser, R.A.; Freeman, T.B.; Olanow, C.W. Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson’s disease. Nat. Med. 2008, 14, 504–506. [Google Scholar] [CrossRef]
- Li, J.Y.; Englund, E.; Holton, J.L.; Soulet, D.; Hagell, P.; Lees, A.J.; Lashley, T.; Quinn, N.P.; Rehncrona, S.; Björklund, A.; et al. Lewy bodies in grafted neurons in subjects with Parkinson’s disease suggest host-to-graft disease propagation. Nat. Med. 2008, 14, 501–503. [Google Scholar] [CrossRef]
- Sandberg, M.K.; Al-Doujaily, H.; Sharps, B.; Clarke, A.R.; Collinge, J. Prion propagation and toxicity in vivo occur in two distinct mechanistic phases. Nature 2011, 470, 540–542. [Google Scholar] [CrossRef]
- Forloni, G.; Artuso, V.; La Vitola, P.; Balducci, C. Oligomeropathies and pathogenesis of Alzheimer and Parkinson’s diseases. Mov. Disord. 2016, 31, 771–781. [Google Scholar] [CrossRef]
- La Vitola, P.; Balducci, C.; Cerovic, M.; Santamaria, G.; Brandi, E.; Grandi, F.; Caldinelli, L.; Colombo, L.; Morgese, M.G.; Trabace, L.; et al. Alpha-synuclein oligomers impair memory through glial cell activation and via Toll-like receptor 2. Brain Behav. Immun. 2018, 69, 591–602. [Google Scholar] [CrossRef] [PubMed]
- Choi, I.; Zhang, Y.; Seegobin, S.P.; Pruvost, M.; Wang, Q.; Purtell, K.; Zhang, B.; Yue, Z. Microglia clear neuron-released α-synuclein via selective autophagy and prevent neurodegeneration. Nat. Commun. 2020, 11, 1386. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Su, Y.; Shi, C.; Wang, T.; Liu, C.; Yang, J.; Zhang, S.; Fan, L.; Zheng, H.; Li, X.; Luo, H.; et al. Dysregulation of peripheral monocytes and pro-inflammation of alpha-synuclein in Parkinson’s disease. J. Neurol. 2022, 269, 6386–6394. [Google Scholar] [CrossRef] [PubMed]
- Venezia, S.; Refolo, V.; Polissidis, A.; Stefanis, L.; Wenning, G.K.; Stefanova, N. Toll-like receptor 4 stimulation with monophosphoryl lipid A ameliorates motor deficits and nigral neurodegeneration triggered by extraneuronal α-synucleinopathy. Mol. Neurodegener. 2017, 12, 52. [Google Scholar] [CrossRef] [PubMed]
- Wijeyekoon, R.S.; Kronenberg-Versteeg, D.; Scott, K.M.; Hayat, S.; Kuan, W.L.; Evans, J.R.; Breen, D.P.; Cummins, G.; Jones, J.L.; Clatworthy, M.R.; et al. Peripheral innate immune and bacterial signals relate to clinical heterogeneity in Parkinson’s disease. Brain Behav. Immun. 2020, 87, 473–488. [Google Scholar] [CrossRef]
- La Vitola, P.; Balducci, C.; Baroni, M.; Artioli, L.; Santamaria, G.; Castiglioni, M.; Cerovic, M.; Colombo, L.; Caldinelli, L.; Pollegioni, L.; et al. Peripheral inflammation exacerbates α-synuclein toxicity and neuropathology in Parkinson’s models. Neuropathol. Appl. Neurobiol. 2021, 47, 43–60. [Google Scholar] [CrossRef]
- Jarrett, J.T.; Lansbury, P.T., Jr. Seeding “one-dimensional crystallization” of amyloid: A pathogenic mechanism in Alzheimer’s disease and scrapie? Cell 1993, 73, 1055–1058. [Google Scholar] [CrossRef]
- Giampà, M.; Amundarain, M.J.; Herrera, M.G.; Tonali, N.; Dodero, V.I. Implementing Complementary Approaches to Shape the Mechanism of α-Synuclein Oligomerization as a Model of Amyloid Aggregation. Molecules 2021, 27, 88. [Google Scholar] [CrossRef]
- Boyer, D.R.; Li, B.; Sun, C.; Fan, W.; Sawaya, M.R.; Jiang, L.; Eisenberg, D.S. Structures of fibrils formed by α-synuclein hereditary disease mutant H50Q reveal new polymorphs. Nat. Struct. Mol. Biol. 2019, 26, 1044–1052. [Google Scholar] [CrossRef]
- Guerrero-Ferreira, R.; Taylor, N.M.; Mona, D.; Ringler, P.; Lauer, M.E.; Riek, R.; Britschgi, M.; Stahlberg, H. Cryo-EM structure of alpha-synuclein fibrils. Elife 2018, 7, e36402. [Google Scholar] [CrossRef]
- Sun, Y.; Hou, S.; Zhao, K.; Long, H.; Liu, Z.; Gao, J.; Zhang, Y.; Su, X.D.; Li, D.; Liu, C. Cryo-EM structure of full-length α-synuclein amyloid fibril with Parkinson’s disease familial A53T mutation. Cell Res. 2020, 30, 360–362. [Google Scholar] [CrossRef] [PubMed]
- Zhao, K.; Li, Y.; Liu, Z.; Long, H.; Zhao, C.; Luo, F.; Sun, Y.; Tao, Y.; Su, X.D.; Li, D.; et al. Parkinson’s disease associated mutation E46K of α-synuclein triggers the formation of a distinct fibril structure. Nat. Commun. 2020, 11, 2643. [Google Scholar] [CrossRef] [PubMed]
- Koga, S.; Sekiya, H.; Kondru, N.; Ross, O.A.; Dickson, D.W. Neuropathology and molecular diagnosis of Synucleinopathies. Mol. Neurodegener. 2021, 16, 83. [Google Scholar] [CrossRef] [PubMed]
- Yang, Y.; Shi, Y.; Schweighauser, M.; Zhang, X.; Kotecha, A.; Murzin, A.G.; Garringer, H.J.; Cullinane, P.W.; Saito, Y.; Foroud, T.; et al. Structures of α-synuclein filaments from human brains with Lewy pathology. Nature 2022, 610, 791–795. [Google Scholar] [CrossRef]
- Lövestam, S.; Schweighauser, M.; Matsubara, T.; Murayama, S.; Tomita, T.; Ando, T.; Hasegawa, K.; Yoshida, M.; Tarutani, A.; Hasegawa, M.; et al. Seeded assembly in vitro does not replicate the structures of α-synuclein filaments from multiple system atrophy. FEBS Open Bio 2021, 11, 999–1013. [Google Scholar] [CrossRef] [PubMed]
- Estaun-Panzano, J.; Arotcarena, M.L.; Bezard, E. Monitoring α-synuclein aggregation. Neurobiol. Dis. 2023, 176, 105966. [Google Scholar] [CrossRef] [PubMed]
- Taylor, A.I.P.; Staniforth, R.A. General Principles Underpinning Amyloid Structure. Front. Neurosci. 2022, 16, 878869. [Google Scholar] [CrossRef]
- Zhang, W.; Falcon, B.; Murzin, A.G.; Fan, J.; Crowther, R.A.; Goedert, M.; Scheres, S.H. Heparin-induced tau filaments are polymorphic and differ from those in Alzheimer’s and Pick’s diseases. Elife 2019, 8, e43584. [Google Scholar] [CrossRef]
- El-Agnaf, O.M.; Irvine, G.B. Aggregation and neurotoxicity of alpha-synuclein and related peptides. Biochem. Soc. Trans. 2002, 30, 559–565. [Google Scholar] [CrossRef]
- Alam, P.; Bousset, L.; Melki, R.; Otzen, D.E. α-Synuclein oligomers and fibrils: A spectrum of species, a spectrum of toxicities. J. Neurochem. 2019, 150, 522–534. [Google Scholar] [CrossRef] [Green Version]
- Conway, K.A.; Harper, J.D.; Lansbury, P.T. Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease. Nat. Med. 1998, 4, 1318–1320. [Google Scholar] [CrossRef] [PubMed]
- Conway, K.A.; Lee, S.J.; Rochet, J.C.; Ding, T.T.; Williamson, R.E.; Lansbury, P.T., Jr. Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson’s disease: Implications for pathogenesis and therapy. Proc. Natl. Acad. Sci. USA 2000, 97, 571–576. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Lashuel, H.A.; Petre, B.M.; Wall, J.; Simon, M.; Nowak, R.J.; Walz, T.; Lansbury, P.T., Jr. Alpha-synuclein, especially the Parkinson’s disease-associated mutants, forms pore-like annular and tubular protofibrils. J. Mol. Biol. 2002, 322, 1089–1102. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Lashuel, H.A.; Hartley, D.; Petre, B.M.; Walz, T.; Lansbury, P.T., Jr. Neurodegenerative disease: Amyloid pores from pathogenic mutations. Nature 2002, 418, 291. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Cremades, N.; Chen, S.W.; Dobson, C.M. Structural Characteristics of α-Synuclein Oligomers. Int. Rev. Cell Mol. Biol. 2017, 329, 79–143. [Google Scholar] [PubMed]
- Ghanem, S.S.; Majbour, N.K.; Vaikath, N.N.; Ardah, M.T.; Erskine, D.; Jensen, N.M.; Fayyad, M.; Sudhakaran, I.P.; Vasili, E.; Melachroinou, K.; et al. α-Synuclein phosphorylation at serine 129 occurs after initial protein deposition and inhibits seeded fibril formation and toxicity. Proc. Natl. Acad. Sci. USA 2022, 119, e2109617119. [Google Scholar] [CrossRef]
- Lyer, A.; Sidhu, A.; Subramaniam, V. How important is the N-terminal acetylation of alpha-synuclein for its function and aggregation into amyloids? Front. Neurosci. 2022, 16, 1003997. [Google Scholar]
- Yoo, H.; Lee, J.; Kim, B.; Moon, H.; Jeong, H.; Lee, K.; Song, W.J.; Hur, J.K.; Oh, Y. Role of post-translational modifications on the alpha-synuclein aggregation-related pathogenesis of Parkinson’s disease. BMB Rep. 2022, 55, 323–335. [Google Scholar] [CrossRef]
- Watson, M.D.; Lee, J.C. N-Terminal Acetylation Affects α-Synuclein Fibril Polymorphism. Biochemistry 2019, 58, 3630–3633. [Google Scholar] [CrossRef]
- Ye, Y.; Klenerman, D.; Finley, D. N-Terminal Ubiquitination of Amyloidogenic Proteins Triggers Removal of Their Oligomers by the Proteasome Holoenzyme. J. Mol. Biol. 2020, 432, 585–596. [Google Scholar] [CrossRef]
- Chen, L.; Wei, Y.; Wang, X.; He, R. Ribosylation rapidly induces alpha-synuclein to form highly cytotoxic molten globules of advanced glycation end products. PLoS ONE 2010, 5, e9052. [Google Scholar]
- Vicente Miranda, H.; Szego, É.M.; Oliveira, L.M.A.; Breda, C.; Darendelioglu, E.; de Oliveira, R.M.; Ferreira, D.G.; Gomes, M.A.; Rott, R.; Oliveira, M.; et al. Glycation potentiates α-synuclein-associated neurodegeneration in synucleinopathies. Brain 2017, 140, 1399–1419. [Google Scholar] [CrossRef] [Green Version]
- Savyon, M.; Engelender, S. SUMOylation in α-Synuclein Homeostasis and Pathology. Front. Aging Neurosci. 2020, 12, 167. [Google Scholar] [CrossRef]
- Cremades, N.; Cohen, S.I.; Deas, E.; Abramov, A.Y.; Chen, A.Y.; Orte, A.; Sandal, M.; Clarke, R.W.; Dunne, P.; Aprile, F.A.; et al. Direct observation of the interconversion of normal and toxic forms of α-synuclein. Cell 2012, 149, 1048–1059. [Google Scholar] [CrossRef] [Green Version]
- De Oliveira, G.A.P.; Silva, J.L. Alpha-synuclein stepwise aggregation reveals features of an early onset mutation in Parkinson’s disease. Commun. Biol. 2019, 2, 374. [Google Scholar] [CrossRef] [Green Version]
- Cascella, R.; Chen, S.W.; Bigi, A.; Camino, J.D.; Xu, C.K.; Dobson, C.M.; Chiti, F.; Cremades, N.; Cecchi, C. The release of toxic oligomers from α-synuclein fibrils induces dysfunction in neuronal cells. Nat. Commun. 2021, 12, 1814. [Google Scholar] [CrossRef]
- Kim, H.Y.; Cho, M.K.; Kumar, A.; Maier, E.; Siebenhaar, C.; Becker, S.; Fernandez, C.O.; Lashuel, H.A.; Benz, R.; Lange, A.; et al. Structural properties of pore-forming oligomers of α-synuclein. JACS 2009, 131, 17482–17489. [Google Scholar] [CrossRef]
- Choi, M.L.; Chappard, A.; Singh, B.P.; Maclachlan, C.; Rodrigues, M.; Fedotova, E.I.; Berezhnov, A.V.; De, S.; Peddie, C.J.; Athauda, D.; et al. Pathological structural conversion of α-synuclein at the mitochondria induces neuronal toxicity. Nat. Neurosci. 2022, 25, 1134–1148. [Google Scholar] [CrossRef]
- Stefanovic, A.N.; Stöckl, M.T.; Claessens, M.M.; Subramaniam, V. α-Synuclein oligomers distinctively permeabilize complex model membranes. FEBS J. 2014, 281, 2838–2850. [Google Scholar] [CrossRef] [Green Version]
- Caruana, M.; Camilleri, A.; Farrugia, M.Y.; Ghio, S.; Jakubíčková, M.; Cauchi, R.J.; Vassallo, N. Extract from the Marine Seaweed Padina pavonica Protects Mitochondrial Biomembranes from Damage by Amyloidogenic Peptides. Molecules 2021, 26, 1444. [Google Scholar] [CrossRef]
- Ganjam, G.K.; Bolte, K.; Matschke, L.A.; Neitemeier, S.; Dolga, A.M.; Höllerhage, M.; Höglinger, G.U.; Adamczyk, A.; Decher, N.; Oertel, W.H.; et al. Mitochondrial damage by α-synuclein causes cell death in human dopaminergic neurons. Cell Death Dis. 2019, 10, 865. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Sekiya, H.; Kowa, H.; Koga, H.; Takata, M.; Satake, W.; Futamura, N.; Funakawa, I.; Jinnai, K.; Takahashi, M.; Kondo, T.; et al. Wide distribution of alpha-synuclein oligomers in multiple system atrophy brain detected by proximity ligation. Acta Neuropathol. 2019, 137, 455–466. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Sekiya, H.; Tsuji, A.; Hashimoto, Y.; Takata, M.; Koga, S.; Nishida, K.; Futamura, N.; Kawamoto, M.; Kohara, N.; Dickson, D.W.; et al. Discrepancy between distribution of alpha-synuclein oligomers and Lewy-related pathology in Parkinson’s disease. Acta Neuropathol. Commun. 2022, 10, 13. [Google Scholar] [CrossRef] [PubMed]
- La Vitola, P.; Beeg, M.; Balducci, C.; Santamaria, G.; Restelli, E.; Colombo, L.; Caldinelli, L.; Pollegioni, L.; Gobbi, M.; Chiesa, R.; et al. Cellular prion protein neither binds to alpha-synuclein oligomers nor mediates their detrimental effects. Brain 2019, 142, 249–254. [Google Scholar] [CrossRef]
- Emin, D.; Zhang, Y.P.; Lobanova, E.; Miller, A.; Li, X.; Xia, Z.; Dakin, H.; Sideris, D.I.; Lam, J.Y.L.; Ranasinghe, R.T.; et al. Small soluble α-synuclein aggregates are the toxic species in Parkinson’s disease. Nat. Commun. 2022, 13, 5512. [Google Scholar] [CrossRef]
- Ubeda-Bañon, I.; Saiz-Sanchez, D.; de la Rosa-Prieto, C.; Martinez-Marcos, A. α-Synuclein in the olfactory system in Parkinson’s disease: Role of neural connections on spreading pathology. Brain Struct. Funct. 2014, 219, 1513–1526. [Google Scholar] [CrossRef]
- Cersosimo, M.G. Propagation of alpha-synuclein pathology from the olfactory bulb: Possible role in the pathogenesis of dementia with Lewy bodies. Cell Tissue Res. 2018, 373, 233–243. [Google Scholar] [CrossRef]
- Marxreiter, F.; Nuber, S.; Kandasamy, M.; Klucken, J.; Aigner, R.; Burgmayer, R.; Couillard-Despres, S.; Riess, O.; Winkler, J.; Winner, B. Changes in adult olfactory bulb neurogenesis in mice expressing the A30P mutant form of alpha-synuclein. Eur. J. Neurosci. 2009, 29, 879–890. [Google Scholar] [CrossRef] [Green Version]
- Taguchi, T.; Ikuno, M.; Hondo, M.; Parajuli, L.K.; Taguchi, K.; Ueda, J.; Sawamura, M.; Okuda, S.; Nakanishi, E.; Hara, J.; et al. α-Synuclein BAC transgenic mice exhibit RBD-like behaviour and hyposmia: A prodromal Parkinson’s disease model. Brain 2020, 43, 249–265. [Google Scholar] [CrossRef] [Green Version]
- Zhang, S.; Xiao, Q.; Le, W. Olfactory dysfunction and neurotransmitter disturbance in olfactory bulb of transgenic mice expressing human A53T mutant α-synuclein. PLoS ONE 2015, 10, e0119928. [Google Scholar] [CrossRef]
- Uemura, N.; Ueda, J.; Yoshihara, T.; Ikuno, M.; Uemura, M.T.; Yamakado, H.; Asano, M.; Trojanowski, J.Q.; Takahashi, R. α-Synuclein Spread from Olfactory Bulb Causes Hyposmia, Anxiety, and Memory Loss in BAC-SNCA Mice. Mov. Disord. 2021, 36, 2036–2047. [Google Scholar] [CrossRef] [PubMed]
- Rey, N.L.; Steiner, J.A.; Maroof, N.; Luk, K.C.; Madaj, Z.; Trojanowski, J.Q.; Lee, V.M.; Brundin, P. Widespread transneuronal propagation of α-synucleinopathy triggered in olfactory bulb mimics prodromal Parkinson’s disease. J. Exp. Med. 2016, 213, 1759–1778. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Rey, N.L.; George, S.; Steiner, J.A.; Madaj, Z.; Luk, K.C.; Trojanowski, J.Q.; Lee, V.M.; Brundin, P. Spread of aggregates after olfactory bulb injection of α-synuclein fibrils is associated with early neuronal loss and is reduced long term. Acta Neuropathol. 2018, 135, 65–83. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Sawamura, M.; Onoe, H.; Tsukada, H.; Isa, K.; Yamakado, H.; Okuda, S.; Ikuno, M.; Hatanaka, Y.; Murayama, S.; Uemura, N.; et al. Lewy Body Disease Primate Model with α-Synuclein Propagation from the Olfactory Bulb. Mov. Disord. 2022, 37, 2033–2044. [Google Scholar] [CrossRef] [PubMed]
- Danzer, K.M.; Krebs, S.K.; Wolff, M.; Birk, G.; Hengerer, B. Seeding induced by alpha-synuclein oligomers provides evidence for spreading of alpha-synuclein pathology. J. Neurochem. 2009, 111, 192–203. [Google Scholar] [CrossRef] [PubMed]
- Danzer, K.M.; Kranich, L.R.; Ruf, W.P.; Cagsal-Getkin, O.; Winslow, A.R.; Zhu, L.; Vanderburg, C.R.; McLean, P.J. Exosomal cell-to-cell transmission of alpha synuclein oligomers. Mol. Neurodegener. 2012, 7, 42. [Google Scholar] [CrossRef] [Green Version]
- Danzer, K.M.; Haasen, D.; Karow, A.R.; Moussaud, S.; Habeck, M.; Giese, A.; Kretzschmar, H.; Hengerer, B.; Kostka, M. Different species of alpha-synuclein oligomers induce calcium influx and seeding. J. Neurosci. 2007, 27, 9220–9232. [Google Scholar] [CrossRef] [Green Version]
- Lee, H.J.; Choi, C.; Lee, S.J. Membrane-bound-synuclein has a high aggregation propensity and the ability to seed the aggregation of the cytosolic form. J. Biol. Chem 2002, 277, 671–678. [Google Scholar] [CrossRef] [Green Version]
- Aulić, S.; Le, T.T.; Moda, F.; Abounit, S.; Corvaglia, S.; Casalis, L.; Gustincich, S.; Zurzolo, C.; Tagliavini, F.; Legname, G. Defined α-synuclein prion-like molecular assemblies spreading in cell culture. BMC Neurosci. 2014, 15, 69. [Google Scholar] [CrossRef] [Green Version]
- Luk, K.C.; Song, C.; O’Brien, P.; Stieber, A.; Branch, J.R.; Brunden, K.R.; Trojanowski, J.Q.; Lee, V.M. Exogenous alpha-synuclein fibrils seed the formation of Lewy body-like intracellular inclusions in cultured cells. Proc. Natl. Acad. Sci. USA 2009, 106, 20051–20056. [Google Scholar] [CrossRef] [Green Version]
- Emmanouilidou, E.; Melachroinou, K.; Roumeliotis, T.; Garbis, S.D.; Ntzouni, M.; Margaritis, L.H.; Stefanis, L.; Vekrellis, K. Cell-produced alpha-synuclein is secreted in a calcium-dependent manner by exosomes and impacts neuronal survival. J. Neurosci. 2010, 30, 6838–6851. [Google Scholar] [CrossRef] [Green Version]
- Delenclos, M.; Trendafilova, T.; Mahesh, D.; Baine, A.M.; Moussaud, S.; Yan, I.K.; Patel, T.; McLean, P.J. Investigation of Endocytic Pathways for the Internalization of Exosome-Associated Oligomeric Alpha-Synuclein. Front. Neurosci. 2017, 11, 172. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Shearer, L.J.; Petersen, N.O.; Woodside, M.T. Internalization of α-synuclein oligomers into SH-SY5Y cells. Biophys. J. 2021, 120, 877–885. [Google Scholar] [CrossRef] [PubMed]
- Zhang, S.; Eitan, E.; Wu, T.Y.; Mattson, M.P. Intercellular transfer of pathogenic α-synuclein by extracellular vesicles is induced by the lipid peroxidation product 4-hydroxynonenal. Neurobiol. Aging. 2018, 61, 52–65. [Google Scholar] [CrossRef] [PubMed]
- Gustafsson, G.; Lööv, C.; Persson, E.; Lázaro, D.F.; Takeda, S.; Bergström, J.; Erlandsson, A.; Sehlin, D.; Balaj, L.; György, B.; et al. Secretion and Uptake of α-Synuclein Via Extracellular Vesicles in Cultured Cells. Cell Mol. Neurobiol. 2018, 38, 1539–1550. [Google Scholar] [CrossRef] [Green Version]
- Zheng, H.; Xie, Z.; Zhang, X.; Mao, J.; Wang, M.; Wei, S.; Fu, Y.; Zheng, H.; He, Y.; Chen, H.; et al. Investigation of α-Synuclein Species in Plasma Exosomes and the Oligomeric and Phosphorylated α-Synuclein as Potential Peripheral Biomarker of Parkinson’s Disease. Neuroscience 2021, 469, 79–90. [Google Scholar] [CrossRef]
- Volpicelli-Daley, L.A.; Luk, K.C.; Lee, V.M. Addition of exogenous α-synuclein preformed fibrils to primary neuronal cultures to seed recruitment of endogenous α-synuclein to Lewy body and Lewy neurite-like aggregates. Nat. Protoc. 2014, 9, 2135–2146. [Google Scholar] [CrossRef] [Green Version]
- Wu, Q.; Takano, H.; Riddle, D.M.; Trojanowski, J.Q.; Coulter, D.A.; Lee, V.M. α-Synuclein (αSyn) Preformed Fibrils Induce Endogenous α-Syn Aggregation, Compromise Synaptic Activity and Enhance Synapse Loss in Cultured Excitatory Hippocampal Neurons. J. Neurosci. 2019, 39, 5080–5094. [Google Scholar] [CrossRef] [Green Version]
- Wu, Q.; Shaikh, M.A.; Meymand, E.S.; Zhang, B.; Luk, K.C.; Trojanowski, J.Q.; Lee, V.M. Neuronal activity modulates alpha-synuclein aggregation and spreading in organotypic brain slice cultures and in vivo. Acta Neuropathol. 2020, 140, 831–849. [Google Scholar] [CrossRef]
- El-Agnaf, O.M.; Jakes, R.; Curran, M.D.; Middleton, D.; Ingenito, R.; Bianchi, E.; Pessi, A.; Neill, D.; Wallace, A. Aggregates from mutant and wild-type alpha-synuclein proteins and NAC peptide induce apoptotic cell death in human neuroblastoma cells by formation of beta-sheet and amyloid-like filaments. FEBS Lett. 1998, 440, 71–75. [Google Scholar] [CrossRef] [Green Version]
- Lücking, C.B.; Brice, A. Alpha-synuclein and Parkinson’s disease. Cell Mol. Life Sci. 2000, 57, 1894–1908. [Google Scholar] [CrossRef] [PubMed]
- Forloni, G.; Bertani, I.; Calella, A.M.; Thaler, F.; Invernizzi, R. Alpha-synuclein and Parkinson’s disease: Selective neurodegenerative effect of alpha-synuclein fragment on dopaminergic neurons in vitro and in vivo. Ann. Neurol. 2000, 47, 632–640. [Google Scholar] [CrossRef] [PubMed]
- Brown, D.R. Oligomeric alpha-synuclein and its role in neuronal death. IUBMB Life 2010, 62, 334–339. [Google Scholar] [CrossRef] [PubMed]
- Celej, M.S.; Sarroukh, R.; Goormaghtigh, E.; Fidelio, G.D.; Ruysschaert, J.M.; Raussens, V. Toxic prefibrillar α-synuclein amyloid oligomers adopt a distinctive antiparallel β-sheet structure. Biochem. J. 2012, 443, 719–726. [Google Scholar] [CrossRef] [PubMed]
- Jiang, Z.; de Messieres, M.; Lee, J.C. Membrane remodeling by α-synuclein and effects on amyloid formation. J. Am. Chem. Soc. 2013, 135, 15970–15973. [Google Scholar] [CrossRef] [Green Version]
- Rockenstein, E.; Nuber, S.; Overk, C.R.; Ubhi, K.; Mante, M.; Patrick, C.; Adame, A.; Trejo-Morales, M.; Gerez, J.; Picotti, P.; et al. Accumulation of oligomer-prone α-synuclein exacerbates synaptic and neuronal degeneration in vivo. Brain 2014, 137, 1496–1513. [Google Scholar] [CrossRef]
- Bigi, A.; Ermini, E.; Chen, S.W.; Cascella, R.; Cecchi, C. Exploring the Release of Toxic Oligomers from α-Synuclein Fibrils with Antibodies and STED Microscopy. Life 2021, 11, 431. [Google Scholar] [CrossRef]
- Prots, I.; Grosch, J.; Brazdis, R.M.; Simmnacher, K.; Veber, V.; Havlicek, S.; Hannappel, C.; Krach, F.; Krumbiegel, M.; Schütz, O.; et al. α-Synuclein oligomers induce early axonal dysfunction in human iPSC-based models of synucleinopathies. Proc. Natl. Acad. Sci. USA 2018, 115, 7813–7818. [Google Scholar] [CrossRef] [Green Version]
- Jin, M.; Matsumoto, S.; Ayaki, T.; Yamakado, H.; Taguchi, T.; Togawa, N.; Konno, A.; Hirai, H.; Nakajima, H.; Komai, S.; et al. DOPAnization of tyrosine in α-synuclein by tyrosine hydroxylase leads to the formation of oligomers. Nat. Commun. 2022, 13, 6880. [Google Scholar] [CrossRef]
- Martin, Z.S.; Neugebauer, V.; Dineley, K.T.; Kayed, R.; Zhang, W.; Reese, L.C.; Taglialatela, G. α-Synuclein oligomers oppose long-term potentiation and impair memory through a calcineurin-dependent mechanism: Relevance to human synucleopathic diseases. J. Neurochem. 2012, 120, 440–452. [Google Scholar] [CrossRef]
- Fortuna, J.T.S.; Gralle, M.; Beckman, D.; Neves, F.S.; Diniz, L.P.; Frost, P.S.; Barros-Aragão, F.; Santos, L.E.; Gonçalves, R.A.; Romão, L.; et al. Brain infusion of α-synuclein oligomers induces motor and non-motor Parkinson’s disease-like symptoms in mice. Behav. Brain Res. 2017, 333, 150–160. [Google Scholar] [CrossRef] [PubMed]
- Boi, L.; Pisanu, A.; Palmas, M.F.; Fusco, G.; Carboni, E.; Casu, M.A.; Satta, V.; Scherma, M.; Janda, E.; Mocci, I.; et al. Modeling Parkinson’s Disease Neuropathology and Symptoms by Intranigral Inoculation of Preformed Human α-Synuclein Oligomers. Int. J. Mol. Sci. 2020, 21, 8535. [Google Scholar] [CrossRef] [PubMed]
- Guiney, S.J.; Adlard, P.A.; Lei, P.; Mawal, C.H.; Bush, A.I.; Finkelstein, D.I.; Ayton, S. Fibrillar α-synuclein toxicity depends on functional lysosomes. J. Biol. Chem. 2020, 295, 17497–17513. [Google Scholar] [CrossRef]
- Peelaerts, W.; Bousset, L.; Van der Perren, A.; Moskalyuk, A.; Pulizzi, R.; Giugliano, M.; Van den Haute, C.; Melki, R.; Baekelandt, V. α-Synuclein strains cause distinct synucleinopathies after local and systemic administration. Nature 2015, 522, 340–344. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Tapias, V.; Hu, X.; Luk, K.C.; Sanders, L.H.; Lee, V.M.; Greenamyre, J.T. Synthetic alpha-synuclein fibrils cause mitochondrial impairment and selective dopamine neurodegeneration in part via iNOS-mediated nitric oxide production. Cell Mol Life Sci. 2017, 74, 2851–2874. [Google Scholar] [CrossRef]
- Zadali, R.; Hassani, V.; Rafiei, Y.; Meratan, A.A.; Mamashli, F.; Nemat-Gorgani, M. A study on the interaction of the amyloid fibrils of α-synuclein and hen egg white lysozyme with biological membranes. Biochim. Biophys. Acta Biomembr. 2022, 1864, 183776. [Google Scholar] [CrossRef]
- Balducci, C.; Forloni, G. In vivo application of beta amyloid oligomers: A simple tool to evaluate mechanisms of action and new therapeutic approaches. Curr. Pharm. Des. 2014, 20, 2491–2505. [Google Scholar] [CrossRef]
- Balducci, C.; Beeg, M.; Stravalaci, M.; Bastone, A.; Sclip, A.; Biasini, E.; Colombo, L.; Manzoni, C.; Borsello, T.; Chiesa, R.; et al. Synthetic amyloid-beta oligomers impair long-term memory independently of cellular prion protein. Proc. Natl. Acad. Sci. USA 2010, 107, 2295–2300. [Google Scholar] [CrossRef] [Green Version]
- Kayed, R.; Sokolov, Y.; Edmonds, B.; McIntire, T.M.; Milton, S.C.; Hall, J.E.; Glabe, C.G. Permeabilization of lipid bilayers is a common conformation-dependent activity of soluble amyloid oligomers in protein misfolding diseases. J. Biol. Chem. 2004, 279, 46363–46366. [Google Scholar] [CrossRef] [Green Version]
- Madhu, P.; Das, D.; Mukhopadhyay, S. Conformation-specific perturbation of membrane dynamics by structurally distinct oligomers of Alzheimer’s amyloid-β peptide. Phys. Chem. Chem. Phys. 2021, 23, 9686–9694. [Google Scholar] [CrossRef]
- Pirhaghi, M.; Frank, S.A.; Alam, P.; Nielsen, J.; Sereikaite, V.; Gupta, A.; Strømgaard, K.; Andreasen, M.; Sharma, D.; Saboury, A.A.; et al. A penetratin-derived peptide reduces the membrane permeabilization and cell toxicity of α-synuclein oligomers. J. Biol. Chem. 2022, 298, 102688. [Google Scholar] [CrossRef] [PubMed]
- Salmona, M.; Forloni, G.; Diomede, L.; Algeri, M.; De Gioia, L.; Angeretti, N.; Giaccone, G.; Tagliavini, F.; Bugiani, O. A neurotoxic and gliotrophic fragment of the prion protein increases plasma membrane microviscosity. Neurobiol. Dis. 1997, 4, 47–57. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Benilova, I.; Karran, E.; De Strooper, B. The toxic Aβ oligomer and Alzheimer’s disease: An emperor in need of clothes. Nat. Neurosci. 2012, 15, 349–357. [Google Scholar] [CrossRef] [PubMed]
- Bahadi, R.; Farrelly, P.V.; Kenna, B.L.; Kourie, J.I.; Tagliavini, F.; Forloni, G.; Salmona, M. Channels formed with a mutant prion protein PrP(82-146) homologous to a 7-kDa fragment in diseased brain of GSS patients. Am. J. Physiol. Cell Physiol. 2003, 285, C862–C872. [Google Scholar] [CrossRef] [Green Version]
- Chen, S.W.; Drakulic, S.; Deas, E.; Ouberai, M.; Aprile, F.A.; Arranz, R.; Ness, S.; Roodveldt, C.; Guilliams, T.; De-Genst, E.J.; et al. Structural characterization of toxic oligomers that are kinetically trapped during α-synuclein fibril formation. Proc. Natl. Acad. Sci. USA 2015, 112, E1994–E2003. [Google Scholar] [CrossRef] [Green Version]
- Stöckl, M.T.; Zijlstra, N.; Subramaniam, V. α-Synuclein oligomers: An amyloid pore? Insights into mechanisms of α-synuclein oligomer-lipid interactions. Mol. Neurobiol. 2013, 47, 613–621. [Google Scholar] [CrossRef] [PubMed]
- Camilleri, A.; Zarb, C.; Caruana, M.; Ostermeier, U.; Ghio, S.; Högen, T.; Schmidt, F.; Giese, A.; Vassallo, N. Mitochondrial membrane permeabilisation by amyloid aggregates and protection by polyphenols. Biochim. Biophys. Acta. 2013, 1828, 2532–2543. [Google Scholar] [CrossRef] [Green Version]
- Luth, E.S.; Stavrovskaya, I.G.; Bartels, T.; Kristal, B.S.; Selkoe, D.J. Soluble, prefibrillar α-synuclein oligomers promote complex I-dependent, Ca2+-induced mitochondrial dysfunction. J. Biol. Chem. 2014, 289, 21490–21507. [Google Scholar] [CrossRef] [Green Version]
- Nakamura, K.; Nemani, V.M.; Azarbal, F.; Skibinski, G.; Levy, J.M.; Egami, K.; Munishkina, L.; Zhang, J.; Gardner, B.; Wakabayashi, J.; et al. Direct membrane association drives mitochondrial fission by the Parkinson disease-associated protein alpha-synuclein. J. Biol. Chem. 2011, 286, 20710–20726. [Google Scholar] [CrossRef] [Green Version]
- Tomagra, G.; Franchino, C.; Cesano, F.; Chiarion, G.; de Lure, A.; Carbone, E.; Calabresi, P.; Mesin, L.; Picconi, B.; Marcantoni, A.; et al. Alpha-synuclein oligomers alter the spontaneous firing discharge of cultured midbrain neurons. Front. Cell Neurosci. 2023, 17, 1078550. [Google Scholar] [CrossRef]
- Corbett, G.T.; Wang, Z.; Hong, W.; Colom-Cadena, M.; Rose, J.; Liao, M.; Asfaw, A.; Hall, T.C.; Ding, L.; DeSousa, A.; et al. PrP is a central player in toxicity mediated by soluble aggregates of neurodegeneration-causing proteins. Acta Neuropathol. 2020, 139, 503–526. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ferreira, D.G.; Temido-Ferreira, M.; Vicente Miranda, H.; Batalha, V.L.; Coelho, J.E.; Szegö, É.M.; Marques-Morgado, I.; Vaz, S.H.; Rhee, J.S.; Schmitz, M.; et al. α-synuclein interacts with PrPC to induce cognitive impairment through mGluR5 and NMDAR2B. Nat. Neurosci. 2017, 20, 1569–1579. [Google Scholar] [CrossRef] [PubMed]
- Maor, G.; Dubreuil, R.R.; Feany, M.B. α-Synuclein promotes neuronal dysfunction and death by disrupting the binding of ankyrin to α-Spectrin. J. Neurosci. 2023, 43, 1614–1626. [Google Scholar] [CrossRef] [PubMed]
- Ordonez, D.G.; Lee, M.K.; Feany, M.B. α-Synuclein induces mitochondrial dysfunction through spectrin and the actin cytoskeleton. Neuron 2018, 97, 108–124.e6. [Google Scholar] [CrossRef]
- Chen, K.; Martens, Y.A.; Meneses, A.; Ryu, D.H.; Lu, W.; Raulin, A.C.; Li, F.; Zhao, J.; Chen, Y.; Jin, Y.; et al. LRP1 is a neuronal receptor for α-synuclein uptake and spread. Mol. Neurodegener. 2022, 17, 57. [Google Scholar] [CrossRef] [PubMed]
- Wilkaniec, A.; Gąssowska, M.; Czapski, G.A.; Cieślik, M.; Sulkowski, G.; Adamczyk, A. P2X7 receptor-pannexin 1 interaction mediates extracellular alpha-synuclein-induced ATP release in neuroblastoma SH-SY5Y cells. Purinergic. Signal 2017, 13, 347–361. [Google Scholar] [CrossRef] [Green Version]
- Wilkaniec, A.; Cieślik, M.; Murawska, E.; Babiec, L.; Gąssowska-Dobrowolska, M.; Pałasz, E.; Jęśko, H.; Adamczyk, A. P2X7 Receptor is Involved in Mitochondrial Dysfunction Induced by Extracellular Alpha Synuclein in Neuroblastoma SH-SY5Y Cells. Int. J. Mol. Sci. 2020, 21, 3959. [Google Scholar] [CrossRef]
- Durante, V.; de Iure, A.; Loffredo, V.; Vaikath, N.; De Risi, M.; Paciotti, S.; Quiroga-Varela, A.; Chiasserini, D.; Mellone, M.; Mazzocchetti, P.; et al. Alpha-synuclein targets GluN2A NMDA receptor subunit causing striatal synaptic dysfunction and visuospatial memory alteration. Brain 2019, 142, 1365–1385. [Google Scholar] [CrossRef] [Green Version]
- Forloni, G.; Balducci, C. Alzheimer’s Disease, Oligomers, and Inflammation. J. Alzheimers. Dis. 2018, 62, 1261–1276. [Google Scholar] [CrossRef] [Green Version]
- Terkelsen, M.H.; Klaestrup, I.H.; Hvingelby, V.; Lauritsen, J.; Pavese, N.; Romero-Ramos, M. Neuroinflammation and Immune Changes in Prodromal Parkinson’s Disease and Other Synucleinopathies. J. Parkinsons. Dis. 2022, 12 (Suppl. S1), S149–S163. [Google Scholar] [CrossRef]
- Cerovic, M.; Forloni, G.; Balducci, C. Neuroinflammation and the Gut Microbiota: Possible Alternative Therapeutic Targets to Counteract Alzheimer’s Disease? Front. Aging Neurosci. 2019, 11, 284. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Saleh, H.A.; Yousef, M.H.; Abdelnaser, A. The Anti-Inflammatory Properties of Phytochemicals and Their Effects on Epigenetic Mechanisms Involved in TLR4/NF-κB-Mediated Inflammation. Front. Immunol. 2021, 12, 606069. [Google Scholar] [CrossRef] [PubMed]
- Tansey, M.G.; Wallings, R.L.; Houser, M.C.; Herrick, M.K.; Keating, C.E.; Joers, V. Inflammation and immune dysfunction in Parkinson disease. Nat. Rev. Immunol. 2022, 22, 657–673. [Google Scholar] [CrossRef] [PubMed]
- Williams, G.P.; Schonhoff, A.M.; Sette, A.; Lindestam Arlehamn, C.S. Central and Peripheral Inflammation: Connecting the Immune Responses of Parkinson’s Disease. J. Parkinsons. Dis. 2022, 12, S129–S136. [Google Scholar] [CrossRef]
- Pant, A.; Bisht, K.S.; Aggarwal, S.; Maiti, T.K. Human gut microbiota and Parkinson’s disease. Prog. Mol. Biol. Transl. Sci. 2022, 192, 281–307. [Google Scholar] [PubMed]
- Ryman, S.; Vakhtin, A.A.; Richardson, S.P.; Lin, H.C. Microbiome-gut-brain dysfunction in prodromal and symptomatic Lewy body diseases. J. Neurol. 2022; Epub ahead of print. [Google Scholar] [CrossRef] [PubMed]
- Parkkinen, L.; Pirttilä, T.; Alafuzoff, I. Applicability of current staging/categorization of alpha-synuclein pathology and their clinical relevance. Acta Neuropathol. 2008, 115, 399–407. [Google Scholar] [CrossRef] [Green Version]
- Braak, H.; de Vos, R.A.; Bohl, J.; Del Tredici, K. Gastric alpha-synuclein immunoreactive inclusions in Meissner’s and Auerbach’s plexuses in cases staged for Parkinson’s disease-related brain pathology. Neurosci. Lett 2006, 396, 67–72. [Google Scholar] [CrossRef]
- Holmqvist, S.; Chutna, O.; Bousset, L.; Aldrin-Kirk, P.; Li, W.; Björklund, T.; Wang, Z.-Y.; Roybon, L. Direct evidence of Parkinson pathology spread from the gastrointestinal tract to the brain in rats. Acta Neuropathol. 2014, 128, 805–820. [Google Scholar] [CrossRef] [Green Version]
- Manfredsson, F.P.; Luk, K.C.; Benskey, M.J.; Gezer, A.; Garcia, J.; Kuhn, N.C.; Sandoval, I.M.; Patterson, J.R.; O’Mara, A.; Yonkers, R.; et al. Induction of alpha-synuclein pathology in the enteric nervous system of the rat and non-human primate results in gastrointestinal dysmotility and transient CNS pathology. Neurobiol. Dis. 2018, 112, 106–118. [Google Scholar] [CrossRef]
- Beach, T.G.; Adler, C.H.; Sue, L.I.; Shill, H.A.; Driver-Dunckley, E.; Mehta, S.H.; Intorcia, A.J.; Glass, M.J.; Walker, J.E.; Arce, R.; et al. Vagus Nerve and Stomach Synucleinopathy in Parkinson’s Disease, Incidental Lewy Body Disease, and Normal Elderly Subjects: Evidence Against the “Body-First” Hypothesis. J. Parkinsons. Dis. 2021, 11, 1833–1843. [Google Scholar] [CrossRef] [PubMed]
- Farrow, S.L.; Cooper, A.A.; O’Sullivan, J.M. Redefining the hypotheses driving Parkinson’s diseases research. NPJ Parkinsons. Dis. 2022, 8, 45. [Google Scholar] [CrossRef] [PubMed]
- Arotcarena, M.L.; Dovero, S.; Prigent, A.; Bourdenx, M.; Camus, S.; Porras, G.; Thiolat, M.L.; Tasselli, M.; Aubert, P.; Kruse, N.; et al. Bidirectional gut-to-brain and brain-to-gut propagation of synucleinopathy in non-human primates. Brain 2020, 143, 1462–1475. [Google Scholar] [CrossRef]
- Kim, S.; Kwon, S.H.; Kam, T.I.; Panicker, N.; Karuppagounder, S.S.; Lee, S.; Lee, J.H.; Kim, W.R.; Kook, M.; Foss, C.A.; et al. Transneuronal Propagation of Pathologic α-Synuclein from the Gut to the Brain Models Parkinson’s Disease. Neuron 2019, 103, 627–641. [Google Scholar] [CrossRef] [PubMed]
- Van Den Berge, N.; Ferreira, N.; Gram, H.; Mikkelsen, T.W.; Alstrup, A.K.O.; Casadei, N.; Tsung-Pin, P.; Riess, O.; Nyengaard, J.R.; Tamgüney, G.; et al. Evidence for bidirectional and trans-synaptic parasympathetic and sympathetic propagation of alpha-synuclein in rats. Acta Neuropathol 2019, 138, 535–550. [Google Scholar] [CrossRef] [Green Version]
- Lee, H.J.; Suk, J.E.; Patrick, C.; Bae, E.J.; Cho, J.H.; Rho, S.; Hwang, D.; Masliah, E.; Lee, S.J. Direct transfer of alpha-synuclein from neuron to astroglia causes inflammatory responses in synucleinopathies. J. Biol. Chem. 2010, 285, 9262–9272. [Google Scholar] [CrossRef] [Green Version]
- Kim, T.K.; Bae, E.J.; Jung, B.C.; Choi, M.; Shin, S.J.; Park, S.J.; Kim, J.T.; Jung, M.K.; Ulusoy, A.; Song, M.Y.; et al. Inflammation promotes synucleinopathy propagation. Exp. Mol. Med. 2022, 54, 2148–2161. [Google Scholar] [CrossRef]
- Sokratous, M.C.; Dardiotis, E.; Hadjigeorgiou, G.M.; Bogdanos, D.; Xiromerisiou, G. Neurodegeneration and Inflammation-An Interesting Interplay in Parkinson’s Disease. Int. J. Mol. Sci. 2020, 21, 8421. [Google Scholar]
- Kishimoto, Y.; Zhu, W.; Hosoda, W.; Sen, J.M.; Mattson, M.P. Chronic Mild Gut Inflammation Accelerates Brain Neuropathology and Motor Dysfunction in α-Synuclein Mutant Mice. Neuromolecular. Med. 2019, 21, 239–249. [Google Scholar] [CrossRef]
- Balducci, C.; Forloni, G. TLR4 in Neurodegenerative Diseases: Alzheimer’s and Parkinson’s Diseases. In The Role of Toll-Like Receptor 4 in Infectious and Non Infectious inflammation; Rossetti, C., Peri, F., Eds.; Springer: Berlin/Heidelberg, Germany, 2021; pp. 105–118. [Google Scholar]
- Kollmann, T.R.; Levy, O.; Montgomery, R.R.; Goriely, S. Innate immune function by Toll-like receptors: Distinct responses in newborns and the elderly. Immunity 2012, 37, 771–783. [Google Scholar] [CrossRef] [Green Version]
- Lehnardt, S.; Henneke, P.; Lien, E.; Kasper, D.L.; Volpe, J.J.; Bechmann, I.; Nitsch, R.; Weber, J.R.; Golenbock, D.T.; Vartanian, T. A mechanism for neurodegeneration induced by group B streptococci through activation of the TLR2/MyD88 pathway in microglia. J. Immunol. 2006, 177, 583–592. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Leitner, G.R.; Wenzel, T.J.; Marshall, N.; Gates, E.J.; Klegeris, A. Targeting toll-like receptor 4 to modulate neuroinflammation in central nervous system disorders. Expert Opin. Ther. Targets 2019, 23, 865–882. [Google Scholar] [CrossRef]
- Rosenberger, K.; Derkow, K.; Dembny, P.; Krüger, C.; Schott, E.; Lehnardt, S. The impact of single and pairwise Toll-like receptor activation on neuroinflammation and neurodegeneration. J. Neuroinflamm. 2014, 11, 166. [Google Scholar] [CrossRef] [Green Version]
- Yang, J.; Wise, L.; Fukuchi, K.I. TLR4 Cross-Talk with NLRP3 Inflammasome and Complement Signaling Pathways in Alzheimer’s Disease. Front. Immunol. 2020, 11, 724. [Google Scholar] [CrossRef] [PubMed]
- Soraci, L.; Gambuzza, M.E.; Biscetti, L.; Laganà, P.; Lo Russo, C.; Buda, A.; Barresi, G.; Corsonello, A.; Lattanzio, F.; Lorello, G.; et al. Toll-like receptors and NLRP3 inflammasome-dependent pathways in Parkinson’s disease: Mechanisms and therapeutic implications. J. Neurol. 2022; Epub ahead of print. [Google Scholar] [CrossRef]
- Ravichandran, K.A.; Heneka, M.T. Inflammasome activation in neurodegenerative diseases. Essays Biochem. 2021, 65, 885–904. [Google Scholar] [PubMed]
- Haque, M.E.; Akther, M.; Jakaria, M.; Kim, I.S.; Azam, S.; Choi, D.K. Targeting the microglial NLRP3 inflammasome and its role in Parkinson’s disease. Mov. Disord. 2020, 35, 20–33. [Google Scholar] [CrossRef]
- Wang, X.J.; Ma, M.M.; Zhou, L.B.; Jiang, X.Y.; Hao, M.M.; Teng, R.K.F.; Wu, E.; Tang, B.S.; Li, J.Y.; Teng, J.F.; et al. Autonomic ganglionic injection of α-synuclein fibrils as a model of pure autonomic failure α-synucleinopathy. Nat. Commun. 2020, 11, 934. [Google Scholar] [CrossRef] [Green Version]
- Williams-Gray, C.H.; Wijeyekoon, R.; Yarnall, A.J.; Lawson, R.A.; Breen, D.P.; Evans, J.R.; Cummins, G.A.; Duncan, G.W.; Khoo, T.K.; Burn, D.J.; et al. Serum immune markers and disease progression in an incident Parkinson’s disease cohort (ICICLE-PD). Mov. Disord. 2016, 31, 995–1003. [Google Scholar] [CrossRef] [Green Version]
- Gordon, R.; Albornoz, E.A.; Christie, D.C.; Langley, M.R.; Kumar, V.; Mantovani, S.; Robertson, A.A.B.; Butler, M.S.; Rowe, D.B.; O’Neill, L.A.; et al. Inflammasome inhibition prevents α-synuclein pathology and dopaminergic neurodegeneration in mice. Sci. Transl. Med. 2018, 10, 465. [Google Scholar] [CrossRef] [Green Version]
- Colonna, M.; Butovsky, O. Microglia Function in the Central Nervous System During Health and Neurodegeneration. Annu. Rev. Immunol. 2017, 35, 441–468. [Google Scholar] [CrossRef] [PubMed]
- Scheiblich, H.; Bousset, L.; Schwartz, S.; Griep, A.; Latz, E.; Melki, R.; Heneka, M.T. Microglial NLRP3 Inflammasome Activation upon TLR2 and TLR5 Ligation by Distinct α-Synuclein Assemblies. J Immunol. 2021, 207, 2143–2154. [Google Scholar] [CrossRef] [PubMed]
- Holbrook, J.A.; Jarosz-Griffiths, H.H.; Caseley, E.; Lara-Reyna, S.; Poulter, J.A.; Williams-Gray, C.H.; Peckham, D.; McDermott, M.F. Neurodegenerative Disease and the NLRP3 Inflammasome. Front. Pharmacol. 2021, 12, 643254. [Google Scholar] [CrossRef] [PubMed]
- Gustot, A.; Gallea, J.I.; Sarroukh, R.; Celej, M.S.; Ruysschaert, J.M.; Raussens, V. Amyloid fibrils are the molecular trigger of inflammation in Parkinson’s disease. Biochem. J. 2015, 471, 323–333. [Google Scholar] [CrossRef] [PubMed]
- Bliederhaeuser, C.; Grozdanov, V.; Speidel, A.; Zondler, L.; Ruf, W.P.; Bayer, H.; Kiechle, M.; Feiler, M.S.; Freischmidt, A.; Brenner, D.; et al. Age-dependent defects of alpha-synuclein oligomer uptake in microglia and monocytes. Acta Neuropathol. 2016, 131, 379–391. [Google Scholar] [CrossRef]
- Du, X.Y.; Xie, X.X.; Liu, R.T. The Role of α-Synuclein Oligomers in Parkinson’s Disease. Int. J. Mol. Sci. 2020, 21, 8645. [Google Scholar] [CrossRef]
- Lv, Q.K.; Tao, K.X.; Wang, X.B.; Yao, X.Y.; Pang, M.Z.; Liu, J.Y.; Wang, F.; Liu, C.F. Role of α-synuclein in microglia: Autophagy and phagocytosis balance neuroinflammation in Parkinson’s disease. Inflamm. Res. 2023; Epub ahead of print. [Google Scholar] [CrossRef]
- Cao, Y.L.; Yang, Y.P.; Mao, C.J.; Zhang, X.Q.; Wang, C.T.; Yang, J.; Lv, D.J.; Wang, F.; Hu, L.F.; Liu, C.F. A role of BAG3 in regulating SNCA/α-synuclein clearance via selective macroautophagy. Neurobiol. Aging 2017, 60, 104–115. [Google Scholar] [CrossRef]
- Ying, Z.M.; Lv, Q.K.; Yao, X.Y.; Dong, A.Q.; Yang, Y.P.; Cao, Y.L.; Wang, F.; Gong, A.P.; Liu, C.F. BAG3 promotes autophagy and suppresses NLRP3 inflammasome activation in Parkinson’s disease. Ann. Transl. Med. 2022, 10, 1218. [Google Scholar] [CrossRef]
- Pellegrini, C.; Antonioli, L.; Calderone, V.; Colucci, R.; Fornai, M.; Blandizzi, C. Microbiota-gut-brain axis in health and disease: Is NLRP3 inflammasome at the crossroads of microbiota-gut-brain communications? Prog. Neurobiol. 2020, 191, 101806. [Google Scholar] [CrossRef]
- Devos, D.; Lebouvier, T.; Lardeux, B.; Biraud, M.; Rouaud, T.; Pouclet, H.; Coron, E.; Bruley des Varannes, S.; Naveilhan, P.; Nguyen, J.M.; et al. Colonic inflammation in Parkinson’s disease. Neurobiol. Dis. 2013, 50, 42–48. [Google Scholar] [CrossRef] [PubMed]
- García-Revilla, J.; Herrera, A.J.; de Pablos, R.M.; Venero, J.L. Inflammatory Animal Models of Parkinson’s Disease. J. Parkinsons. Dis. 2022, 12 (Suppl. S1), S165–S182. [Google Scholar] [CrossRef] [PubMed]
- Chen, C.; Mossman, E.; Malko, P.; McDonald, D.; Blain, A.P.; Bone, L.; Erskine, D.; Filby, A.; Vincent, A.E.; Hudson, G.; et al. Astrocytic Changes in Mitochondrial Oxidative Phosphorylation Protein Levels in Parkinson’s Disease. Mov. Disord. 2022, 37, 302–314. [Google Scholar] [CrossRef] [PubMed]
- Wang, C.; Yang, T.; Liang, M.; Xie, J.; Song, N. Astrocyte dysfunction in Parkinson’s disease: From the perspectives of transmitted α-synuclein and genetic modulation. Transl. Neurodegener. 2021, 10, 39. [Google Scholar] [CrossRef] [PubMed]
- Kuter, K.; Olech, Ł.; Głowacka, U. Prolonged Dysfunction of Astrocytes and Activation of Microglia Accelerate Degeneration of Dopaminergic Neurons in the Rat Substantia Nigra and Block Compensation of Early Motor Dysfunction Induced by 6-OHDA. Mol. Neurobiol. 2018, 55, 3049–3066. [Google Scholar] [CrossRef] [Green Version]
- Ramos-Gonzalez, P.; Mato, S.; Chara, J.C.; Verkhratsky, A.; Matute, C.; Cavaliere, F. Astrocytic atrophy as a pathological feature of Parkinson’s disease with LRRK2 mutation. NPJ Parkinsons. Dis. 2021, 7, 31. [Google Scholar] [CrossRef]
- Brandebura, A.N.; Paumier, A.; Onur, T.S.; Allen, N.J. Astrocyte contribution to dysfunction, risk and progression in neurodegenerative disorders. Nat. Rev. Neurosci. 2023, 24, 23–39. [Google Scholar] [CrossRef]
- Jankovic, J.; Tan, E.K. Parkinson’s disease: Etiopathogenesis and treatment. J. Neurol. Neurosurg. Psychiatry 2020, 91, 795–808. [Google Scholar] [CrossRef] [PubMed]
- Feany, M.B.; Bender, W.W. A Drosophila model of Parkinson’s disease. Nature 2000, 404, 394–398. [Google Scholar] [CrossRef]
- Xu, M.; Loa-Kum-Cheung, W.; Zhang, H.; Quinn, R.J.; Mellick, G.D. Identification of a New α-Synuclein Aggregation Inhibitor via Mass Spectrometry Based Screening. ACS Chem. Neurosci. 2019, 10, 2683–2691. [Google Scholar] [CrossRef]
- Auluck, P.K.; Bonini, N.M. Pharmacological prevention of Parkinson disease in Drosophila. Nat. Med. 2002, 8, 1185–1186. [Google Scholar] [CrossRef] [PubMed]
- Auluck, P.K.; Chan, H.Y.; Trojanowski, J.Q.; Lee, V.M.; Bonini, N.M. Chaperone suppression of alpha-synuclein toxicity in a Drosophila model for Parkinson’s disease. Science 2002, 295, 865–868. [Google Scholar] [CrossRef] [PubMed]
- Paleologou, K.E.; Irvine, G.B.; El-Agnaf, O.M. Alpha-synuclein aggregation in neurodegenerative diseases and its inhibition as a potential therapeutic strategy. Biochem. Soc. Trans. 2005, 33, 1106–1110. [Google Scholar] [CrossRef] [PubMed]
- Windisch, M.; Hutter-Paier, B.; Rockenstein, E.; Hashimoto, M.; Mallory, M.; Masliah, E. Development of a new treatment for Alzheimer’s disease and Parkinson’s disease using anti-aggregatory beta-synuclein-derived peptides. J. Mol. Neurosci. 2002, 19, 63–69. [Google Scholar] [CrossRef] [PubMed]
- Vidović, M.; Rikalovic, M.G. Alpha-Synuclein Aggregation Pathway in Parkinson’s Disease: Current Status and Novel Therapeutic Approaches. Cells 2022, 11, 1732. [Google Scholar] [CrossRef] [PubMed]
- Masuda, M.; Suzuki, N.; Taniguchi, S.; Oikawa, T.; Nonaka, T.; Iwatsubo, T.; Hisanaga, S.; Goedert, M.; Hasegawa, M. Small molecule inhibitors of alpha-synuclein filament assembly. Biochemistry 2006, 45, 6085–6094. [Google Scholar] [CrossRef] [PubMed]
- Pujols, J.; Peña-Díaz, S.; Conde-Giménez, M.; Pinheiro, F.; Navarro, S.; Sancho, J.; Ventura, S. High-Throughput Screening Methodology to Identify Alpha-Synuclein Aggregation Inhibitors. Int. J. Mol. Sci. 2017, 18, 478. [Google Scholar] [CrossRef] [Green Version]
- Xu, J.; Kao, S.Y.; Lee, F.J.; Song, W.; Jin, L.W.; Yankner, B.A. Dopamine-dependent neurotoxicity of alpha-synuclein: A mechanism for selective neurodegeneration in Parkinson disease. Nat. Med. 2002, 8, 600–606. [Google Scholar] [CrossRef]
- Hideshima, M.; Kimura, Y.; Aguirre, C.; Kakuda, K.; Takeuchi, T.; Choong, C.J.; Doi, J.; Nabekura, K.; Yamaguchi, K.; Nakajima, K.; et al. Two-step screening method to identify α-synuclein aggregation inhibitors for Parkinson’s disease. Sci. Rep. 2022, 12, 351. [Google Scholar] [CrossRef]
- Casalino, E.; Stine, L.B.; Corin, A.J.; Thai, C.T.; Quiroz, J.; Wilson, S.C.; Labow, M.; Mittal, S. A novel high-throughput screening strategy for targeting alpha-synuclein and other long-lived proteins. SLAS Discov. 2022, 27, 349–357. [Google Scholar] [CrossRef]
- De Luca, L.; Vittorio, S.; Peña-Díaz, S.; Pitasi, G.; Fornt-Suñé, M.; Bucolo, F.; Ventura, S.; Gitto, R. Ligand-Based Discovery of a Small Molecule as Inhibitor of α-Synuclein Amyloid Formation. Int. J. Mol. Sci. 2022, 23, 14844. [Google Scholar] [CrossRef] [PubMed]
- Grosso Jasutkar, H.; Oh, S.E.; Mouradian, M.M. Therapeutics in the Pipeline Targeting α-Synuclein for Parkinson’s Disease. Pharmacol. Rev. 2022, 74, 207–237. [Google Scholar] [CrossRef] [PubMed]
- Wagner, J.; Ryazanov, S.; Leonov, A.; Levin, J.; Shi, S.; Schmidt, F.; Prix, C.; Pan-Montojo, F.; Bertsch, U.; Mitteregger-Kretzschmar, G.; et al. Anle138b: A novel oligomer modulator for disease-modifying therapy of neurodegenerative diseases such as prion and Parkinson’s disease. Acta Neuropathol. 2013, 125, 795–813. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Antonschmidt, L.; Matthes, D.; Dervişoğlu, R.; Frieg, B.; Dienemann, C.; Leonov, A.; Nimerovsky, E.; Sant, V.; Ryazanov, S.; Giese, A.; et al. The clinical drug candidate anle138b binds in a cavity of lipidic α-synuclein fibrils. Nat. Commun. 2022, 13, 5385. [Google Scholar] [CrossRef]
- Levin, J.; Schmidt, F.; Boehm, C.; Prix, C.; Bötzel, K.; Ryazanov, S.; Leonov, A.; Griesinger, C.; Giese, A. The oligomer modulator anle138b inhibits disease progression in a Parkinson mouse model even with treatment started after disease onset. Acta Neuropathol. 2014, 127, 779–780. [Google Scholar] [CrossRef] [Green Version]
- Wegrzynowicz, M.; Bar-On, D.; Calo’, L.; Anichtchik, O.; Iovino, M.; Xia, J.; Ryazanov, S.; Leonov, A.; Giese, A.; Dalley, J.W.; et al. Depopulation of dense α-synuclein aggregates is associated with rescue of dopamine neuron dysfunction and death in a new Parkinson’s disease model. Acta Neuropathol. 2019, 138, 575–595. [Google Scholar] [CrossRef] [Green Version]
- Fellner, L.; Kuzdas-Wood, D.; Levin, J.; Ryazanov, S.; Leonov, A.; Griesinger, C.; Giese, A.; Wenning, G.K.; Stefanova, N. Anle138b Partly Ameliorates Motor Deficits Despite Failure of Neuroprotection in a Model of Advanced Multiple System Atrophy. Front. Neurosci. 2016, 10, 99. [Google Scholar] [CrossRef] [Green Version]
- Heras-Garvin, A.; Weckbecker, D.; Ryazanov, S.; Leonov, A.; Griesinger, C.; Giese, A.; Wenning, G.K.; Stefanova, N. Anle138b modulates α-synuclein oligomerization and prevents motor decline and neurodegeneration in a mouse model of multiple system atrophy. Mov. Disord. 2019, 34, 255–263. [Google Scholar] [CrossRef] [Green Version]
- Lemos, M.; Venezia, S.; Refolo, V.; Heras-Garvin, A.; Schmidhuber, S.; Giese, A.; Leonov, A.; Ryazanov, S.; Griesinger, C.; Galabova, G.; et al. Targeting α-synuclein by PD03 AFFITOPE® and Anle138b rescues neurodegenerative pathology in a model of multiple system atrophy: Clinical relevance. Transl. Neurodegener 2020, 9, 38. [Google Scholar] [CrossRef]
- Levin, J.; Sing, N.; Melbourne, S.; Morgan, A.; Mariner, C.; Spillantini, M.G.; Wegrzynowicz, M.; Dalley, J.W.; Langer, S.; Ryazanov, S.; et al. Safety, tolerability and pharmacokinetics of the oligomer modulator anle138b with exposure levels sufficient for therapeutic efficacy in a murine Parkinson model: A randomised, double-blind, placebo-controlled phase 1a trial. EBioMedicine 2022, 80, 104021. [Google Scholar] [CrossRef]
- Dou, T.; Kurouski, D. Phosphatidylcholine and Phosphatidylserine Uniquely Modify the Secondary Structure of α-Synuclein Oligomers Formed in Their Presence at the Early Stages of Protein Aggregation. ACS Chem. Neurosci. 2022, 13, 2380–2385. [Google Scholar] [CrossRef] [PubMed]
- Limbocker, R.; Staats, R.; Chia, S.; Ruggeri, F.S.; Mannini, B.; Xu, C.K.; Perni, M.; Cascella, R.; Bigi, A.; Sasser, L.R.; et al. Squalamine and Its Derivatives Modulate the Aggregation of Amyloid-β and α-Synuclein and Suppress the Toxicity of Their Oligomers. Front. Neurosci. 2021, 15, 680026. [Google Scholar] [CrossRef] [PubMed]
- Perni, M.; Galvagnion, C.; Maltsev, A.; Meisl, G.; Müller, M.B.; Challa, P.K.; Kirkegaard, J.B.; Flagmeier, P.; Cohen, S.I.; Cascella, R.; et al. A natural product inhibits the initiation of α-synuclein aggregation and suppresses its toxicity. Proc. Natl. Acad. Sci. USA 2017, 114, E1009–E1017. [Google Scholar] [CrossRef] [Green Version]
- West, C.L.; Mao, Y.K.; Delungahawatta, T.; Amin, J.Y.; Farhin, S.; McQuade, R.M.; Diwakarla, S.; Pustovit, R.; Stanisz, A.M.; Bienenstock, J.; et al. Squalamine Restores the Function of the Enteric Nervous System in Mouse Models of Parkinson’s Disease. J. Parkinsons. Dis. 2020, 10, 1477–1491. [Google Scholar] [CrossRef] [PubMed]
- Camilleri, M.; Subramanian, T.; Pagan, F.; Isaacson, S.; Gil, R.; Hauser, R.A.; Feldman, M.; Goldstein, M.; Kumar, R.; Truong, D.; et al. Oral ENT-01 Targets Enteric Neurons to Treat Constipation in Parkinson Disease: A Randomized Controlled Trial. Ann. Intern. Med. 2022, 175, 1666–1674. [Google Scholar] [CrossRef]
- Limbocker, R.; Errico, S.; Barbut, D.; Knowles, T.P.J.; Vendruscolo, M.; Chiti, F.; Zasloff, M. Squalamine and trodusquemine: Two natural products for neurodegenerative diseases, from physical chemistry to the clinic. Nat. Prod. Rep. 2022, 39, 742–753. [Google Scholar] [CrossRef] [PubMed]
- Perni, M.; Flagmeier, P.; Limbocker, R.; Cascella, R.; Aprile, F.A.; Galvagnion, C.; Heller, G.T.; Meisl, G.; Chen, S.W.; Kumita, J.R.; et al. Multistep Inhibition of α-Synuclein Aggregation and Toxicity in Vitro and in Vivo by Trodusquemine. ACS Chem. Biol. 2018, 13, 2308–2319. [Google Scholar] [CrossRef]
- Barletti, B.; Lucchesi, G.; Muscat, S.; Errico, S.; Barbut, D.; Danani, A.; Zasloff, M.; Grasso, G.; Chiti, F.; Caminati, G. Reorganization of the outer layer of a model of the plasma membrane induced by a neuroprotective aminosterol. Colloids Surf. B Biointerfaces 2022, 222, 113115. [Google Scholar] [CrossRef]
- Meade, R.M.; Morris, K.J.; Watt, K.J.C.; Williams, R.J.; Mason, J.M. The Library Derived 4554W Peptide Inhibits Primary Nucleation of α-Synuclein. J. Mol. Biol. 2020, 432, 166706. [Google Scholar] [CrossRef]
- Sangwan, S.; Sahay, S.; Murray, K.A.; Morgan, S.; Guenther, E.L.; Jiang, L.; Williams, C.K.; Vinters, H.V.; Goedert, M.; Eisenberg, D.S. Inhibition of synucleinopathic seeding by rationally designed inhibitors. Elife 2020, 9, e46775. [Google Scholar] [CrossRef]
- Soto, C.; Sigurdsson, E.M.; Morelli, L.; Kumar, R.A.; Castaño, E.M.; Frangione, B. Beta-sheet breaker peptides inhibit fibrillogenesis in a rat brain model of amyloidosis: Implications for Alzheimer’s therapy. Nat. Med. 1998, 4, 822–826. [Google Scholar] [CrossRef] [PubMed]
- Soto, C.; Kascsak, R.J.; Saborío, G.P.; Aucouturier, P.; Wisniewski, T.; Prelli, F.; Kascsak, R.; Mendez, E.; Harris, D.A.; Ironside, J.; et al. Reversion of prion protein conformational changes by synthetic beta-sheet breaker peptides. Lancet 2000, 355, 192–197. [Google Scholar] [CrossRef] [PubMed]
- Jin, J.W.; Fan, X.; Del Cid-Pellitero, E.; Liu, X.X.; Zhou, L.; Dai, C.; Gibbs, E.; He, W.; Li, H.; Wu, X.; et al. Development of an α-synuclein knockdown peptide and evaluation of its efficacy in Parkinson’s disease models. Commun. Biol. 2021, 4, 232. [Google Scholar] [CrossRef] [PubMed]
- Mitra, A.; Sarkar, N. Sequence and structure-based peptides as potent amyloid inhibitors: A review. Arch. Biochem. Biophys. 2020, 695, 108614. [Google Scholar] [CrossRef]
- Popova, B.; Wang, D.; Rajavel, A.; Dhamotharan, K.; Lázaro, D.F.; Gerke, J.; Uhrig, J.F.; Hoppert, M.; Outeiro, T.F.; Braus, G.H. Identification of Two Novel Peptides that Inhibit α-Synuclein Toxicity and Aggregation. Front. Mol. Neurosci. 2021, 14, 659926. [Google Scholar] [CrossRef]
- Schenk, D.B.; Koller, M.; Ness, D.K.; Griffith, S.G.; Grundman, M.; Zago, W.; Soto, J.; Atiee, G.; Ostrowitzki, S.; Kinney, G.G. First-in-human assessment of PRX002, an anti-α-synuclein monoclonal antibody, in healthy volunteers. Mov. Disord. 2017, 32, 211–218. [Google Scholar] [CrossRef]
- Morgan, D.; Diamond, D.M.; Gottschall, P.E.; Ugen, K.E.; Dickey, C.; Hardy, J.; Duff, K.; Jantzen, P.; DiCarlo, G.; Wilcock, D.; et al. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer’s disease. Nature 2000, 408, 982–985. [Google Scholar] [CrossRef]
- van Dyck, C.H.; Swanson, C.J.; Aisen, P.; Bateman, R.J.; Chen, C.; Gee, M.; Kanekiyo, M.; Li, D.; Reyderman, L.; Cohen, S.; et al. Lecanemab in Early Alzheimer’s Disease. N. Engl. J. Med. 2023, 388, 9–21. [Google Scholar] [CrossRef]
- Masliah, E.; Rockenstein, E.; Adame, A.; Alford, M.; Crews, L.; Hashimoto, M.; Seubert, P.; Lee, M.; Goldstein, J.; Chilcote, T.; et al. Effects of alpha-synuclein immunization in a mouse model of Parkinson’s disease. Neuron 2005, 46, 857–868. [Google Scholar] [CrossRef] [Green Version]
- Masliah, E.; Rockenstein, E.; Mante, M.; Crews, L.; Spencer, B.; Adame, A.; Patrick, C.; Trejo, M.; Ubhi, K.; Rohn, T.T.; et al. Passive immunization reduces behavioral and neuropathological deficits in an alpha-synuclein transgenic model of Lewy body disease. PLoS ONE 2011, 6, e19338. [Google Scholar] [CrossRef] [Green Version]
- Mandler, M.; Valera, E.; Rockenstein, E.; Weninger, H.; Patrick, C.; Adame, A.; Santic, R.; Meindl, S.; Vigl, B.; Smrzka, O.; et al. Next-generation active immunization approach for synucleinopathies: Implications for Parkinson’s disease clinical trials. Acta Neuropathol. 2014, 127, 861–879. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Volc, D.; Poewe, W.; Kutzelnigg, A.; Lührs, P.; Thun-Hohenstein, C.; Schneeberger, A.; Galabova, G.; Majbour, N.; Vaikath, N.; El-Agnaf, O.; et al. Safety and immunogenicity of the α-synuclein active immunotherapeutic PD01A in patients with Parkinson’s disease: A randomised, single-blinded, phase 1 trial. Lancet Neurol. 2020, 19, 591–600. [Google Scholar] [CrossRef] [PubMed]
- Meissner, W.G.; Traon, A.P.; Foubert-Samier, A.; Galabova, G.; Galitzky, M.; Kutzelnigg, A.; Laurens, B.; Lührs, P.; Medori, R.; Péran, P.; et al. A Phase 1 Randomized Trial of Specific Active α-Synuclein Immunotherapies PD01A and PD03A in Multiple System Atrophy. Mov. Disord. 2020, 35, 1957–1965. [Google Scholar] [CrossRef]
- Poewe, W.; Volc, D.; Seppi, K.; Medori, R.; Lührs, P.; Kutzelnigg, A.; Djamshidian, A.; Thun-Hohenstein, C.; Meissner, W.G.; Rascol, O.; et al. Safety and Tolerability of Active Immunotherapy Targeting α-Synuclein with PD03A in Patients with Early Parkinson’s Disease: A Randomized, Placebo-Controlled, Phase 1 Study. J. Parkinsons. Dis. 2021, 11, 1079–1089. [Google Scholar] [CrossRef] [PubMed]
- Yu, H.J.; Thijssen, E.; van Brummelen, E.; van der Plas, J.L.; Radanovic, I.; Moerland, M.; Hsieh, E.; Groeneveld, G.J.; Dodart, J.C. A Randomized First-in-Human Study with UB-312, a UBITh® α-Synuclein Peptide Vaccine. Mov. Disord. 2022, 37, 1416–1424. [Google Scholar] [CrossRef]
- Nimmo, J.T.; Verma, A.; Dodart, J.C.; Wang, C.Y.; Savistchenko, J.; Melki, R.; Carare, R.O.; Nicoll, J.A.R. Novel antibodies detect additional α-synuclein pathology in synucleinopathies: Potential development for immunotherapy. Alzheimers Res. Ther. 2020, 12, 159. [Google Scholar] [CrossRef] [PubMed]
- Nimmo, J.T.; Smith, H.; Wang, C.Y.; Teeling, J.L.; Nicoll, J.A.R.; Verma, A.; Dodart, J.C.; Liu, Z.; Lin, F.; Carare, R.O. Immunisation with UB-312 in the Thy1SNCA mouse prevents motor performance deficits and oligomeric α-synuclein accumulation in the brain and gut. Acta Neuropathol. 2022, 143, 55–73. [Google Scholar] [CrossRef]
- Schenk, D.; Barbour, R.; Dunn, W.; Gordon, G.; Grajeda, H.; Guido, T.; Hu, K.; Huang, J.; Johnson-Wood, K.; Khan, K.; et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999, 400, 173–177. [Google Scholar] [CrossRef]
- Jankovic, J.; Goodman, I.; Safirstein, B.; Marmon, T.K.; Schenk, D.B.; Koller, M.; Zago, W.; Ness, D.K.; Griffith, S.G.; Grundman, M.; et al. Safety and Tolerability of Multiple Ascending Doses of PRX002/RG7935, an Anti-α-Synuclein Monoclonal Antibody, in Patients with Parkinson Disease: A Randomized Clinical Trial. JAMA Neurol. 2018, 75, 1206–1214. [Google Scholar] [CrossRef] [Green Version]
- Pagano, G.; Taylor, K.I.; Anzures-Cabrera, J.; Marchesi, M.; Simuni, T.; Marek, K.; Postuma, R.B.; Pavese, N.; Stocchi, F.; Azulay, J.P.; et al. Trial of Prasinezumab in Early-Stage Parkinson’s Disease. N. Engl. J. Med. 2022, 387, 421–432. [Google Scholar] [CrossRef]
- Sevigny, J.; Chiao, P.; Bussière, T.; Weinreb, P.H.; Williams, L.; Maier, M.; Dunstan, R.; Salloway, S.; Chen, T.; Ling, Y.; et al. The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease. Nature 2016, 537, 50–56. [Google Scholar] [CrossRef] [PubMed]
- Weihofen, A.; Liu, Y.; Arndt, J.W.; Huy, C.; Quan, C.; Smith, B.A.; Baeriswyl, J.L.; Cavegn, N.; Senn, L.; Su, L.; et al. Development of an aggregate-selective, human-derived α-synuclein antibody BIIB054 that ameliorates disease phenotypes in Parkinson’s disease models. Neurobiol. Dis. 2019, 124, 276–288. [Google Scholar] [CrossRef]
- Brys, M.; Fanning, L.; Hung, S.; Ellenbogen, A.; Penner, N.; Yang, M.; Welch, M.; Koenig, E.; David, E.; Fox, T.; et al. Randomized phase I clinical trial of anti-α-synuclein antibody BIIB054. Mov. Disord. 2019, 34, 1154–1163. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Lang, A.E.; Siderowf, A.D.; Macklin, E.A.; Poewe, W.; Brooks, D.J.; Fernandez, H.H.; Rascol, O.; Giladi, N.; Stocchi, F.; Tanner, C.M.; et al. Trial of Cinpanemab in Early Parkinson’s Disease. N. Engl. J. Med. 2022, 387, 408–420. [Google Scholar] [CrossRef] [PubMed]
- Schofield, D.J.; Irving, L.; Calo, L.; Bogstedt, A.; Rees, G.; Nuccitelli, A.; Narwal, R.; Petrone, M.; Roberts, J.; Brown, L.; et al. Preclinical development of a high affinity α-synuclein antibody, MEDI1341, that can enter the brain, sequester extracellular α-synuclein and attenuate α-synuclein spreading in vivo. Neurobiol. Dis. 2019, 132, 104582. [Google Scholar] [CrossRef]
- Brendza, R.; Gao, X.; Stark, K.L.; Lin, H.; Lee, S.H.; Hu, C.; Cai, H.; Di Cara, D.; Hsiao, Y.C.; Ngu, H.; et al. Anti-α-synuclein c-terminal antibodies block PFF uptake and accumulation of phospho-synuclein in preclinical models of Parkinson’s disease. Neurobiol. Dis. 2022, 177, 105969. [Google Scholar] [CrossRef] [PubMed]
- Jensen, P.H.; Schlossmacher, M.G.; Stefanis, L. Who Ever Said It Would Be Easy? Reflecting on Two Clinical Trials Targeting α-Synuclein. Mov. Disord. 2023; Epub ahead of print. [Google Scholar] [CrossRef]
- Forloni, G. Alzheimer’s disease: From basic science to precision medicine approach. BMJ Neurol. Open. 2020, 2, e000079. [Google Scholar] [CrossRef]
- Höllerhage, M.; Wolff, A.; Chakroun, T.; Evsyukov, V.; Duan, L.; Chua, O.W.; Tang, Q.; Koeglsperger, T.; Höglinger, G.U. Binding Stability of Antibody-α-Synuclein Complexes Predicts the Protective Efficacy of Anti-α-synuclein Antibodies. Mol. Neurobiol. 2022, 59, 3980–3995. [Google Scholar] [CrossRef]
- Nguyen, L.T.N.; Nguyen, H.D.; Kim, Y.J.; Nguyen, T.T.; Lai, T.T.; Lee, Y.K.; Ma, H.I.; Kim, Y.E. Role of NLRP3 Inflammasome in Parkinson’s Disease and Therapeutic Considerations. J. Parkinsons. Dis. 2022, 12, 2117–2133. [Google Scholar] [CrossRef]
- Dutta, D.; Jana, M.; Majumder, M.; Mondal, S.; Roy, A.; Pahan, K. Selective targeting of the TLR2/MyD88/NF-κB pathway reduces α-synuclein spreading in vitro and in vivo. Nat. Commun. 2021, 12, 5382. [Google Scholar] [CrossRef] [PubMed]
- Sun, L.; Jiang, W.W.; Wang, Y.; Yuan, Y.S.; Rong, Z.; Wu, J.; Fan, Y.; Lu, M.; Zhang, K.Z. Phosphorylated α-synuclein aggregated in Schwann cells exacerbates peripheral neuroinflammation and nerve dysfunction in Parkinson’s disease through TLR2/NF-κB pathway. Cell Death Discov. 2021, 7, 289. [Google Scholar] [CrossRef] [PubMed]
- Xia, X.; Li, Z.; Liu, K.; Wu, Y.; Jiang, D.; Lai, Y. Staphylococcal LTA-Induced miR-143 Inhibits Propionibacterium acnes-Mediated Inflammatory Response in Skin. J. Investig. Dermatol. 2016, 136, 621–630. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kim, C.; Ho, D.H.; Suk, J.E.; You, S.; Michael, S.; Kang, J.; Lee, S.J.; Masliah, E.; Hwang, D.; Lee, H.J.; et al. Neuron-released oligomeric α-synuclein is an endogenous agonist of TLR2 for paracrine activation of microglia. Nat. Commun. 2013, 4, 1562. [Google Scholar] [CrossRef] [Green Version]
- Kumari, M.; Hanpude, P.; Maiti, T.K. α-Synuclein Exhibits Differential Membrane Perturbation, Nucleation, and TLR2 Binding through Its Secondary Structure. ACS Chem. Neurosci. 2020, 11, 4203–4214. [Google Scholar] [CrossRef]
- Kim, C.; Rockenstein, E.; Spencer, B.; Kim, H.K.; Adame, A.; Trejo, M. Antagonizing Neuronal Toll-like Receptor 2 Prevents Synucleinopathy by Activating Autophagy. Cell Rep. 2015, 13, 771–782. [Google Scholar] [CrossRef] [Green Version]
- Kwon, S.; Iba, M.; Masliah, E.; Kim, C. Targeting Microglial and Neuronal Toll-like Receptor 2 in Synucleinopathies. Exp. Neurobiol. 2019, 28, 547–553. [Google Scholar] [CrossRef] [Green Version]
- Chedid, J.; Labrador-Garrido, A.; Zhong, S.; Gao, J.; Zhao, Y.; Perera, G.; Kim, W.S.; Halliday, G.M.; Dzamko, N. A small molecule toll-like receptor antagonist rescues α-synuclein fibril pathology. J. Biol. Chem. 2022, 298, 102260. [Google Scholar] [CrossRef]
- Kouli, A.; Horne, C.B.; Williams-Gray, C.H. Toll-like receptors and their therapeutic potential in Parkinson’s disease and α-synucleinopathies. Brain Behav. Imm. 2019, 81, 41–51. [Google Scholar]
- Xia, Y.; Zhang, G.; Kou, L.; Yin, S.; Han, C.; Hu, J.; Wan, F.; Sun, Y.; Wu, J.; Li, Y.; et al. Reactive microglia enhance the transmission of exosomal α-synuclein via toll-like receptor 2. Brain 2021, 144, 2024–2037. [Google Scholar] [CrossRef]
- Balducci, C.; Santamaria, G.; La Vitola, P.; Brandi, E.; Grandi, F.; Viscomi, A.R. Doxycycline counteracts neuroinflammation restoring memory in Alzheimer’s disease mouse models. Neurobiol. Agin. 2018, 70, 128–139. [Google Scholar] [CrossRef] [PubMed]
- Forloni, G.; Iussich, S.; Awan, T.; Colombo, L.; Angeretti, N.; Girola, L.; Bertani, I.; Poli, G.; Caramelli, M.; Bruzzone, M.; et al. Tetracyclines affect prion infectivity. Proc. Natl. Acad. Sci. USA 2002, 99, 10849–10854. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Haïk, S.; Marcon, G.; Mallet, A.; Tettamanti, M.; Welaratne, A.; Giaccone, G.; Azimi, S.; Pietrini, V.; Fabreguettes, J.R.; Imperiale, D.; et al. Doxycycline in Creutzfeldt-Jakob disease: A phase 2, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2014, 13, 150–158. [Google Scholar] [CrossRef] [PubMed]
- Balducci, C.; Forloni, G. Doxycycline for Alzheimer’s Disease: Fighting β-Amyloid Oligomers and Neuroinflammation. Front. Pharmacol. 2019, 10, 738. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- La Vitola, P.; Artioli, L.; Cerovic, M.; Poletto, C.; Dacomo, L.; Leva, S.; Balducci, C.; Forloni, G. Repositioning Doxycycline for treating Parkinson’s Disease: Evidence from a pre-clinical mouse model. Parkinsonism. Relat. Dis. 2023, 106, 105229. [Google Scholar] [CrossRef]
- Balducci, C.; Frasca, A.; Zotti, M.; La Vitola, P.; Mhillaj, E.; Grigoli, E.; Iacobellis, M.; Grandi, F.; Messa, M.; Colombo, L.; et al. Toll-like receptor 4-dependent glial cell activation mediates the impairment in memory establishment induced by β-amyloid oligomers in an acute mouse model of Alzheimer’s disease. Brain Behav. Immun. 2017, 60, 188–197. [Google Scholar] [CrossRef]
- Tagliavini, F.; Forloni, G.; Colombo, L.; Rossi, G.; Girola, L.; Canciani, B.; Angeretti, N.; Giampaolo, L.; Peressini, E.; Awan, T.; et al. Tetracycline affects abnormal properties of synthetic PrP peptides and PrP(Sc) in vitro. J. Mol. Biol. 2000, 300, 1309–1322. [Google Scholar] [CrossRef]
- González-Lizárraga, F.; Socías, S.B.; Ávila, C.L.; Torres-Bugeau, C.M.; Barbosa, L.R.; Binolfi, A.; Sepúlveda-Díaz, J.E.; Del-Bel, E.; Fernandez, C.O.; Papy-Garcia, D.; et al. Repurposing doxycycline for synucleinopathies: Remodelling of α-synuclein oligomers towards non-toxic parallel beta-sheet structured species. Sci. Rep. 2017, 7, 41755. [Google Scholar] [CrossRef] [Green Version]
- Dominguez-Meijide, A.; Parrales, V.; Vasili, E.; González-Lizárraga, F.; König, A.; Lázaro, D.F.; Lannuzel, A.; Haik, S.; Del Bel, E.; Chehín, R.; et al. Doxycycline inhibits α-synuclein-associated pathologies in vitro and in vivo. Neurobiol. Dis. 2021, 151, 105256. [Google Scholar] [CrossRef]
- Forloni, G.; La Vitola, P.; Cerovic, M.; Balducci, C. Inflammation and Parkinson’s disease pathogenesis: Mechanisms and therapeutic insight. Prog. Mol. Biol. Transl. Sci. 2021, 177, 175–202. [Google Scholar]
- Dos Santos Pereira, M.; do Nascimento, G.C.; Bortolanza, M.; Michel, P.P.; Raisman-Vozari, R.; Del Bel, E. Doxycycline attenuates l-DOPA-induced dyskinesia through an anti-inflammatory effect in a hemiparkinsonian mouse model. Front. Pharmacol. 2022, 13, 1045465. [Google Scholar] [CrossRef] [PubMed]
- Bortolanza, M.; Nascimento, G.C.; Socias, S.B.; Ploper, D.; Chehín, R.N.; Raisman-Vozari, R.; Del-Bel, E. Tetracycline repurposing in neurodegeneration: Focus on Parkinson’s disease. J. Neural. Transm. 2018, 125, 1403–1415. [Google Scholar] [CrossRef] [PubMed]
- Forloni, G.; Tettamanti, M.; Lucca, U.; Albanese, Y.; Quaglio, E.; Chiesa, R.; Villani, F.; Erbetta, E.; Redaelli, V.; Tagliavini, F.; et al. Preventive study in subjects at risk of FFI: Innovative approach to rare diseases. Prion 2015, 9, 75–79. [Google Scholar] [CrossRef] [PubMed]
- Forloni, G.; Roiter, I.; Artuso, V.; Marcon, M.; Colesso, W.; Luban, E.; Lucca, U.; Tettamanti, M.; Pupillo, E.; Redaelli, V.; et al. Preventive pharmacological treatment in subjects at risk for fatal familial insomnia: Science and public engagement. Prion 2022, 16, 66–77. [Google Scholar] [CrossRef]
- Lucchetti, J.; Fracasso, C.; Balducci, C.; Passoni, A.; Forloni, G.; Salmona, M.; Gobbi, M. Plasma and Brain Concentrations of Doxycycline after Single and Repeated Doses in Wild-Type and APP23 Mice. J. Pharmacol. Exp. Ther. 2019, 368, 32–40. [Google Scholar] [CrossRef] [Green Version]
- Naoi, M.; Maruyama, W.; Shamoto-Nagai, M. Disease-modifying treatment of Parkinson’s disease by phytochemicals: Targeting multiple pathogenic factors. J. Neural. Transm. 2022, 129, 737–753. [Google Scholar] [CrossRef]
- Zhong, J.; Li, M.; Xu, J.; Dong, W.; Qin, Y.; Qiu, S.; Li, X.; Wang, H. Roflupram attenuates α-synuclein-induced cytotoxicity and promotes the mitochondrial translocation of Parkin in SH-SY5Y cells overexpressing A53T mutant α-synuclein. Toxicol. Appl. Pharmacol. 2022, 436, 115859. [Google Scholar] [CrossRef]
- Umeda, T.; Hatanaka, Y.; Sakai, A.; Tomiyama, T. Nasal Rifampicin Improves Cognition in a Mouse Model of Dementia with Lewy Bodies by Reducing α-Synuclein Oligomers. Int. J. Mol. Sci. 2021, 22, 8453. [Google Scholar] [CrossRef]
- Yurtsever, İ.; Üstündağ, Ü.V.; Ünal, İ.; Ateş, P.S.; Emekli-Alturfan, E. Rifampicin decreases neuroinflammation to maintain mitochondrial function and calcium homeostasis in rotenone-treated zebrafish. Drug Chem. Toxicol. 2022, 45, 1544–1551. [Google Scholar] [CrossRef]
- Acuña, L.; Corbalán, N.S.; Raisman-Vozari, R. Rifampicin quinone pretreatment improves neuronal survival by modulating microglia inflammation induced by α-synuclein. Neural Regen. Res. 2020, 15, 1473–1474. [Google Scholar] [CrossRef]
- Acuña, L.; Hamadat, S.; Corbalán, N.S.; González-Lizárraga, F.; Dos-Santos-Pereira, M.; Rocca, J.; Díaz, J.S.; Del-Bel, E.; Papy-García, D.; Chehín, R.N.; et al. Rifampicin and Its Derivative Rifampicin Quinone Reduce Microglial Inflammatory Responses and Neurodegeneration Induced In Vitro by α-Synuclein Fibrillary Aggregates. Cells 2019, 8, 776. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Bi, W.; Cheng, X.; Zeng, Z.; Zhou, R.; Luo, R.; Zhang, J.; Zhu, L. Rifampicin ameliorates lipopolysaccharide-induced cognitive and motor impairments via inhibition of the TLR4/MyD88/NF-κB signaling pathway in mice. Neurol. Res. 2021, 43, 358–371. [Google Scholar] [CrossRef] [PubMed]
- Liang, Y.; Zheng, D.; Peng, S.; Lin, D.; Jing, X.; Zeng, Z.; Chen, Y.; Huang, K.; Xie, Y.; Zhou, T.; et al. Rifampicin attenuates rotenone-treated microglia inflammation via improving lysosomal function. Toxicol. In Vitro 2020, 63, 104690. [Google Scholar] [CrossRef] [PubMed]
- Bi, W.; Zhu, L.; Wang, C.; Liang, Y.; Liu, J.; Shi, Q.; Tao, E. Rifampicin inhibits microglial inflammation and improves neuron survival against inflammation. Brain Res. 2011, 13, 12–20. [Google Scholar] [CrossRef] [PubMed]
- Eschlböck, S.; Krismer, F.; Wenning, G.K. Interventional trials in atypical parkinsonism. Parkinsonism. Relat. Disord. 2016, 22 (Suppl. S1), S82–S92. [Google Scholar] [CrossRef]
- Singer, W.; Low, P.A. Optimizing clinical trial design for multiple system atrophy: Lessons from the rifampicin study. Clin. Auton. Res. 2015, 25, 47–52. [Google Scholar] [CrossRef] [Green Version]
- Yulug, B.; Hanoglu, L.; Ozansoy, M.; Isık, D.; Kilic, U.; Kilic, E.; Schabitz, W.R. Therapeutic role of rifampicin in Alzheimer’s disease. Psychiatry Clin. Neurosci. 2018, 72, 152–159. [Google Scholar] [CrossRef] [Green Version]
- Brás, I.C.; Khani, M.H.; Vasili, E.; Möbius, W.; Riedel, D.; Parfentev, I.; Gerhardt, E.; Fahlbusch, C.; Urlaub, H.; Zweckstetter, M.; et al. Molecular Mechanisms Mediating the Transfer of Disease-Associated Proteins and Effects on Neuronal Activity. J. Parkinsons. Dis. 2022, 12, 2397–2422. [Google Scholar] [CrossRef]
- Kim, C.; Spencer, B.; Rockenstein, E.; Yamakado, H.; Mante, M.; Adame, A.; Fields, J.A.; Masliah, D.; Iba, M.; Lee, H.J.; et al. Immunotherapy targeting toll-like receptor 2 alleviates neurodegeneration in models of synucleinopathy by modulating α-synuclein transmission and neuroinflammation. Mol. Neurodegener. 2018, 13, 43. [Google Scholar] [CrossRef]
- Al-Qassabi, A.; Tsao, T.S.; Racolta, A.; Kremer, T.; Cañamero, M.; Belousov, A.; Santana, M.A.; Beck, R.C.; Zhang, H.; Meridew, J.; et al. Immunohistochemical Detection of Synuclein Pathology in Skin in Idiopathic Rapid Eye Movement Sleep Behavior Disorder and Parkinsonism. Mov. Disord. 2021, 36, 895–904. [Google Scholar] [CrossRef]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the author. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Forloni, G. Alpha Synuclein: Neurodegeneration and Inflammation. Int. J. Mol. Sci. 2023, 24, 5914. https://doi.org/10.3390/ijms24065914
Forloni G. Alpha Synuclein: Neurodegeneration and Inflammation. International Journal of Molecular Sciences. 2023; 24(6):5914. https://doi.org/10.3390/ijms24065914
Chicago/Turabian StyleForloni, Gianluigi. 2023. "Alpha Synuclein: Neurodegeneration and Inflammation" International Journal of Molecular Sciences 24, no. 6: 5914. https://doi.org/10.3390/ijms24065914